

EXHIBIT Q

3 of 24 DOCUMENTS

Copyright 2007 PR Newswire Association LLC.
All Rights Reserved.
PR Newswire US

June 19, 2007 Tuesday 3:02 PM GMT

LENGTH: 783 words

HEADLINE: Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation

DATELINE: NEW YORK June 19

BODY:

NEW YORK, June 19 /PRNewswire-FirstCall/ -- Sanofi-aventis (Paris Bourse: Euronext: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb Company (New York: NYSE: BMY) announced today that the U.S. District Court for the Southern District of New York has upheld the validity and enforceability of U.S. patent 4,847,265 covering clopidogrel bisulfate, the active ingredient in Plavix(R), maintaining the main patent protection for this product in the United States until November 2011.

The Court also ruled that Apotex's generic clopidogrel bisulfate infringes sanofi-aventis' patent, and has enjoined Apotex from marketing this product in the United States until the patent expires.

About sanofi-aventis

Sanofi-aventis is one of the world's leading pharmaceutical companies, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (Euronext: SAN) and in New York (NYSE:SNY).

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Forward Looking Statements

For sanofi-aventis

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially

Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation PR Newswire US June 19, 2007
Tuesday 3:02 PM GMT

from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include risks that may arise from the outcome of any appeal, the adverse impact of generic product distributed into the market by Apotex, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

For Bristol-Myers Squibb

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things risks that may arise from the outcome of any appeal, the adverse impact of generic product distributed into the market by Apotex and the potential launch of a generic clopidogrel bisulfate product by other entities. For further details and a discussion of these and other risks and uncertainties, see the company's current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K for the year ended December 31, 2006, furnished to and filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: MEDIA, Jean-Marc Podvin, 33-1-53-77-42-23,
jean-marc.podvin@sanofi-aventis.com ; or Tony Plohoros, +1-908-591-2839,
tony.plohoros@bms.com ; or INVESTORS, Sanjay Gupta, 33-1-53-77-45-45,
sanjay.gupta@sanofi-aventis.com ; or John Elicker, +1-212-546-3775,
john.ellicker@bms.com

Web site: <http://www.bms.com/>

SOURCE Bristol-Myers Squibb Company

URL: <http://www.prnewswire.com>

LOAD-DATE: June 20, 2007

EXHIBIT R

BMY Equity

Date	Px Last
3/21/2006	22.83
3/22/2006	25.24
3/23/2006	25.5
3/24/2006	25.52
3/27/2006	25.11
3/28/2006	24.89
3/29/2006	24.94
3/30/2006	24.95
3/31/2006	24.61
4/3/2006	24.71
4/4/2006	24.75
4/5/2006	24.54
4/6/2006	24.81
4/7/2006	24.51
4/10/2006	24.27
4/11/2006	24.16
4/12/2006	24.06
4/13/2006	24.04
4/17/2006	24.45
4/18/2006	24.83
4/19/2006	24.73
4/20/2006	24.69
4/21/2006	24.8
4/24/2006	24.59
4/25/2006	24.69
4/26/2006	24.97
4/27/2006	25.27
4/28/2006	25.38
5/1/2006	25
5/2/2006	24.99
5/3/2006	24.89
5/4/2006	25.03
5/5/2006	25.28
5/8/2006	25.11
5/9/2006	25.06
5/10/2006	24.95
5/11/2006	24.62
5/12/2006	24.29
5/15/2006	24.46
5/16/2006	24.57
5/17/2006	24.13
5/18/2006	24.15
5/19/2006	24.17
5/22/2006	23.86
5/23/2006	23.99
5/24/2006	23.97
5/25/2006	24.61
5/26/2006	24.95
5/30/2006	24.56

5/31/2006	24.55
6/1/2006	25.15
6/2/2006	25.27
6/5/2006	25.16
6/6/2006	25
6/7/2006	24.9
6/8/2006	25.25
6/9/2006	24.95
6/12/2006	24.48
6/13/2006	24.82
6/14/2006	24.75
6/15/2006	25.27
6/16/2006	25.18
6/19/2006	25.42
6/20/2006	25.56
6/21/2006	25.72
6/22/2006	25.63
6/23/2006	25.51
6/26/2006	25.72
6/27/2006	25.29
6/28/2006	25.25
6/29/2006	25.7
6/30/2006	25.86
7/3/2006	25.74
7/5/2006	25.22
7/6/2006	25.39
7/7/2006	25.33
7/10/2006	25.38
7/11/2006	25.48
7/12/2006	25.08
7/13/2006	24.78
7/14/2006	24.56
7/17/2006	24.66
7/18/2006	24.63
7/19/2006	25.55
7/20/2006	25.64
7/21/2006	25.51
7/24/2006	25.96
7/25/2006	25.89
7/26/2006	25.99
7/27/2006	24.04
7/28/2006	24.47
7/31/2006	23.97
8/1/2006	23.8
8/2/2006	23.69
8/3/2006	23.79
8/4/2006	22.75
8/7/2006	22.77
8/8/2006	21.21
8/9/2006	21.12
8/10/2006	20.83

8/11/2006	20.24
8/14/2006	20.41
8/15/2006	20.79
8/16/2006	21.08
8/17/2006	21.48
8/18/2006	21.64
8/21/2006	21.55
8/22/2006	21.84
8/23/2006	21.63
8/24/2006	21.64
8/25/2006	21.68
8/28/2006	21.72
8/29/2006	21.93
8/30/2006	21.98
8/31/2006	21.75
9/1/2006	22.95
9/5/2006	22.78
9/6/2006	22.63
9/7/2006	22.71
9/8/2006	23.18
9/11/2006	23.39
9/12/2006	24.32
9/13/2006	24.81
9/14/2006	24.68
9/15/2006	24.92
9/18/2006	24.88
9/19/2006	24.71
9/20/2006	24.89
9/21/2006	24.71
9/22/2006	25.06
9/25/2006	25.07
9/26/2006	25.1
9/27/2006	25
9/28/2006	24.85
9/29/2006	24.92
10/2/2006	24.68
10/3/2006	24.82
10/4/2006	24.62
10/5/2006	24.52
10/6/2006	24.42
10/9/2006	24.38
10/10/2006	24.49
10/11/2006	24.3
10/12/2006	24.6
10/13/2006	24.55
10/16/2006	24.52
10/17/2006	24.46
10/18/2006	24.73
10/19/2006	24.65
10/20/2006	24.49
10/23/2006	24.57

10/24/2006	24.75
10/25/2006	24.66
10/26/2006	24.53
10/27/2006	24.69
10/30/2006	24.33
10/31/2006	24.75
11/1/2006	24.62
11/2/2006	24.47
11/3/2006	24.53
11/6/2006	24.73
11/7/2006	25.08
11/8/2006	24.81
11/9/2006	24.58
11/10/2006	24.42
11/13/2006	24.41
11/14/2006	24.44
11/15/2006	24.5
11/16/2006	24.66
11/17/2006	24.8
11/20/2006	24.55
11/21/2006	24.5
11/22/2006	24.73
11/24/2006	24.47
11/27/2006	24.59
11/28/2006	24.63
11/29/2006	24.79
11/30/2006	24.83
12/1/2006	24.84
12/4/2006	25.24
12/5/2006	25.29
12/6/2006	25.39
12/7/2006	25.25
12/8/2006	25.35
12/11/2006	25.42
12/12/2006	25.46
12/13/2006	25.51
12/14/2006	25.59
12/15/2006	25.61
12/18/2006	25.53
12/19/2006	25.65
12/20/2006	25.77
12/21/2006	26.05
12/22/2006	26
12/26/2006	26.06
12/27/2006	26.29
12/28/2006	26.31
12/29/2006	26.32
1/3/2007	26.38
1/4/2007	26.69
1/5/2007	26.18
1/8/2007	26.1

1/9/2007	26.21
1/10/2007	26.2
1/11/2007	26.54
1/12/2007	26.25
1/16/2007	26.57
1/17/2007	26.87
1/18/2007	26.67
1/19/2007	26.63
1/22/2007	26.48
1/23/2007	26.67
1/24/2007	26.99
1/25/2007	26.28
1/26/2007	26.21
1/29/2007	27.43
1/30/2007	28.03
1/31/2007	28.79
2/1/2007	28.8
2/2/2007	28.64
2/5/2007	28.73
2/6/2007	28.75
2/7/2007	28.86
2/8/2007	28.7
2/9/2007	28.52
2/12/2007	27.59
2/13/2007	27.59
2/14/2007	27.72
2/15/2007	27.77
2/16/2007	27.64
2/20/2007	27.42
2/21/2007	27.11
2/22/2007	27.09
2/23/2007	27.05
2/26/2007	27.19
2/27/2007	26.36
2/28/2007	26.38
3/1/2007	26.64
3/2/2007	26.42
3/5/2007	26.35
3/6/2007	27.01
3/7/2007	27.12
3/8/2007	27.16
3/9/2007	26.92
3/12/2007	27.36
3/13/2007	26.8
3/14/2007	27.02
3/15/2007	27.12
3/16/2007	26.82
3/19/2007	26.94
3/20/2007	27.15
3/21/2007	27.71
3/22/2007	27.79

3/23/2007	27.6
3/26/2007	27.62
3/27/2007	27.8
3/28/2007	27.62
3/29/2007	27.91
3/30/2007	27.76
4/2/2007	27.88
4/3/2007	27.54
4/4/2007	27.78
4/5/2007	27.82
4/9/2007	27.66
4/10/2007	27.79
4/11/2007	27.52
4/12/2007	27.55
4/13/2007	28.32
4/16/2007	28.46
4/17/2007	28.29
4/18/2007	28.26
4/19/2007	28.42
4/20/2007	28.67
4/23/2007	28.51
4/24/2007	28.78
4/25/2007	29.7
4/26/2007	29.23
4/27/2007	29.17
4/30/2007	28.86
5/1/2007	28.68
5/2/2007	28.7
5/3/2007	29.34
5/4/2007	30.02
5/7/2007	30.11
5/8/2007	30.21
5/9/2007	30.25
5/10/2007	29.88
5/11/2007	30.24
5/14/2007	30.09
5/15/2007	30.23
5/16/2007	30.08
5/17/2007	30.21
5/18/2007	30.45
5/21/2007	30.31
5/22/2007	30.22
5/23/2007	30
5/24/2007	30.03
5/25/2007	30.05
5/29/2007	30.1
5/30/2007	30.12
5/31/2007	30.31
6/1/2007	30.48
6/4/2007	30.44
6/5/2007	30.42

6/6/2007	30.17
6/7/2007	29.17
6/8/2007	29.27
6/11/2007	29.18
6/12/2007	28.69
6/13/2007	29.74
6/14/2007	29.83
6/15/2007	30.76
6/18/2007	30.31
6/19/2007	31.58

EXHIBIT S

Attn: Business/City Editors
August 8, 2006
For Immediate Release

Apotex Launches First Generic Plavix®

Consumers Have Immediate Access to an Affordable Version of this Important Product.

Weston, FL (August 8, 2006) — Apotex Corp. announced that it has today launched clopidogrel bisulfate 75 mg tablets. Clopidogrel is the generic equivalent of Sanofi's Plavix®, which is marketed in the U.S. by Bristol Myers Squibb.

As the first generic company to file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) for clopidogrel, Apotex will have 180 days of market exclusivity for the product. Sales for clopidogrel 75 mg tablets in the U.S. for the twelve month period ending June 2006 are approximately \$3.77 billion according to IMS Health.

On July 28, the States' Attorneys General reviewing the modified settlement submitted in June by Apotex, BMS, and Sanofi to the Federal Trade Commission (FTC) and the states rejected the agreement. The proposed settlement, which was first announced in March, halted the trial over the infringement case filed by Sanofi/BMS against Apotex over U.S. Patent No. 4,847,265 (the '265 patent) that had been scheduled for June.

Apotex Chief Executive Officer Dr. Barry Sherman said: "Apotex believes its clopidogrel launch to be the largest and most successful launch in the history of the generic industry. We are confident that the patent will be held invalid and that the courts will find inequitable conduct before the Patent Office on the part of Sanofi. Accordingly, Apotex has launched prior to trial so that patients and public and private health care payers can begin benefiting from a quality, low-cost alternative to Plavix® immediately rather than years from now."

"There should be no mistaking," Sherman added "that our decision to launch a generic version of this blockbuster product at risk is a testament to our commitment to patients, consumers, and taxpayers."

The U.S. Food and Drug Administration approved Apotex's ANDA for clopidogrel in January following the expiration of the automatic 30 month stay of approval imposed by federal law when a brand company files an infringement suit against a generic manufacturer challenging its patents. At the time of the ANDA's approval, Apotex was in the midst of patent litigation with Sanofi-Aventis concerning clopidogrel in the U.S. District Court of the Southern District of New York, over the validity and enforceability the '265 patent.

In March, Apotex, Sanofi and BMS announced a proposed settlement of the litigation.

After reviewing the proposed settlement, the States' Attorneys General advised that they would not approve the agreement in its then current form. In June, Apotex, BMS, and Sanofi announced a modified agreement had been submitted to the FTC and the states for review. Both agreements would have resolved the litigation and would have granted Apotex a license to market the generic product several months in advance of the expiration of the patent in return for settling the suit. On July 28 the States' Attorneys General announced their rejection of the modified agreement. The latter agreement contained provisions assuring a smooth launch by Apotex in the event approval of the agreement's settlement terms was not obtained. Under the agreement, Sanofi and BMS have agreed not to seek a temporary restraining order in the event Apotex launched sales of the generic product and not to seek a preliminary injunction until at least five business days after Apotex began shipments. In the event Sanofi and BMS ultimately seek a preliminary injunction, Apotex believes it has strong defenses to such an effort.

As a result, Apotex has decided to immediately launch clopidogrel.

Apotex' clopidogrel tablets are packaged in bottles of 30s, 90s, 1000s, and 100 count unit dose blisters.

The Apotex Group manufactures more than 200 different high-quality generic pharmaceuticals, used by millions of patients worldwide. Its product line includes oral solids, liquids, injectables, nasal sprays, ophthalmics, and inhalation solutions.

Plavix® is a registered trademark of Sanofi-Aventis.

Apotex Corp. is the U.S. subsidiary of Apotex Inc., the largest Canadian-owned manufacturer of prescription drugs. Through its sales and marketing headquarters in Weston, Florida and operations center in Indianapolis, Apotex Corp. is committed to providing safe and affordable generic medicines. Products manufactured and marketed by the Apotex Group are sold in 115 countries around the world. For more information visit www.apotexcorp.com.

-30-

For further information:

Mr. Elie Betito
Director Public & Government Affairs
Tel: 416-749-9300 Ext. 7366
Cell: 416-558-5491
ebetito@apotex.com

Maintained by Apotex Inc., Canada
Privacy Policy | Accessibility | Site Terms | ©Apotex Inc. 2007
Last Modified: August 15, 2006 1:18:15 PM

EXHIBIT T

1 of 1 DOCUMENT

Copyright 2006 Newark Morning Ledger Co.
All Rights Reserved
The Star-Ledger (Newark, New Jersey)

August 9, 2006 Wednesday
FINAL EDITION

SECTION: BUSINESS; Pg. 59

LENGTH: 767 words

HEADLINE: Generic Plavix hits the market 2

BYLINE: GEORGE E. JORDAN, STAR-LEDGER STAFF

BODY:

After days of speculation, a Canadian drugmaker yesterday announced it began selling copycat versions of the blood-thinner Plavix, sending shares of Bristol-Myers Squibb into a tailspin amid concern about the company's top-selling drug.

The move by Apotex represents a major threat to Bristol and its partner, Sanofi-Aventis, which disclosed in a Securities and Exchange Commission filing yesterday they had given up some of their legal rights to fight Apotex.

Plavix generated a total of \$6.3 billion in revenue last year for Bristol-Myers, which owns the U.S. marketing rights to the anti-clotting drug, and Sanofi, which discovered Plavix and owns the non-American marketing rights.

Bristol's shares fell 6.9 percent, while Sanofi's stock lost less than 1 percent.

The nation's three biggest pharmaceutical benefits managers - Caremark RX, Express Scripts and Franklin Lakes-based Medco Health Solutions - said yesterday they would begin filling mail-order prescriptions with generic Plavix tomorrow. Their shares rose modestly on heavy volume.

Medco's 60 million subscribers represent a quarter of Plavix sales in the United States.

The announcement prompted a mutiny by Wall Street analysts, who speculated Bristol-Myers may be forced to slash its dividend. Only a week ago, many of the same experts predicted a generic Plavix launch was unlikely.

Analysts from A.G. Edwards, Deutsche Bank, Sanford C. Bernstein and Merrill Lynch all suggested Bristol may be forced to cut its dividend by half. Michael Krensavage, an analyst with Raymond James, circulated projections that without Plavix, Bristol's breakup value was as little as \$13.75 a share. Only two weeks ago, the stock was trading above \$25.

"We recommend investors avoid both Bristol-Myers Squibb and Sanofi-Aventis until more clarity is gained on the Plavix situation," Timothy Anderson, a pharmaceutical analyst at Prudential Financial, said in a note to investors.

Generic drugs are priced much cheaper than brand-name medicines, and can lead to an 80 percent plunge in the name-brand revenue.

Generic Plavix hits the market 2 The Star-Ledger (Newark, New Jersey) August 9, 2006 Wednesday

Apotex declined to disclose its price, which Wall Street analysts estimated will be 30 percent to 40 percent less than the \$15 a pill for Plavix.

However much cheaper, a generic version of the popular blood-thinner would be a major blow to Bristol, which depends on Plavix for an estimated 30 percent to 40 percent of its earnings per share.

Peter Dolan, Bristol's chief executive, said in an open letter to employees, "It is too early to determine what effect this action by Apotex could have on the Plavix business," but he warned plans for the Plavix franchise "cannot be sustained if we no longer have exclusivity for this product."

Apotex launched its copycat versions after a group of state attorneys general vetoed Bristol's proposed settlement of a patent dispute with Apotex that would have kept generic Plavix off the market until 2011. The U.S. Department of Justice has opened a criminal investigation into the settlement, which was announced in March.

"There should be no mistaking that our decision to launch a generic version of this blockbuster product at risk is a testament to our commitment to patients, consumers and taxpayers," Apotex Chief Executive Barry Sherman said in a news release.

By launching generic Plavix without waiting for a court ruling, Apotex is selling copycat versions "at risk," meaning that under U.S. patent law, it could be forced to reimburse Bristol-Myers and Sanofi for their lost profits.

Apotex received approval in January from the Food and Drug Administration to produce and sell the generic Plavix, known by the name clopidogrel, in the United States. However, Bristol and Sanofi claim the patent on the drug remains in force until 2011.

Tony Plohoros, a Bristol spokesman, said the company was weighing its options and would "vigorously defend our intellectual property rights." Among Bristol's options are to slash the price of Plavix, launch its own generic version or sue Apotex and seek an injunction blocking sales of the generic.

Bristol and Sanofi said they must wait five days before seeking an injunction to stop Apotex, which has fought over the Plavix patent for years. U.S. District Judge Sidney Stein in New York on Monday denied a request to temporarily block generic Plavix sales until the lawsuit is ruled on, Sanofi said in its statement.

Even if a judge grants an injunction, Bristol's sales of Plavix still may substantially suffer if Apotex ships large amounts of generic Plavix to distributors.

George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.

GRAPHIC: CHART: BRISTOL-MYERS SQUIBB

LOAD-DATE: April 19, 2007

EXHIBIT U

1 of 1 DOCUMENT

Copyright 2006 The Houston Chronicle Publishing Company
All Rights Reserved
The Houston Chronicle

August 9, 2006 Wednesday
3 STAR EDITION

SECTION: BUSINESS; Pg. 3

LENGTH: 385 words

HEADLINE: PATENT DISPUTE;

Drug fight escalates;

Bristol-Myers shares slip after rival launches generic version of blood thinner

BYLINE: THERESA AGOVINO, WALLACE WITKOWSKI, Associated Press

DATeline: NEW YORK

BODY:

NEW YORK - Bristol-Myers Squibb Co. shares plunged nearly 7 percent Tuesday amid concerns that its earnings and dividend are in serious jeopardy now that a generic version of its best-selling medicine has been launched by Apotex Corp.

Some patients will likely to be able to purchase the generic version of blood thinner Plavix beginning today. Rite Aid Corp. spokeswoman Jody Cook said the company expects to have the drug at ``most, if not all" its 3,300 stores by then.

Apotex declined to say how much it was charging for its pills. Plavix pills have a wholesale price of \$3.89 each.

Apotex's announcement Tuesday that it had begun selling the drug came just hours after Bristol-Myers said it was expecting that in an SEC filing.

Bristol-Myers and Sanofi-Aventis, which sells Plavix outside the U.S., reached a deal earlier this year with Apotex to pay it at least \$40 million to end a patent challenge in return for allowing it to introduce a version of Plavix - in 2011, months before the patent expired.

The Canadian generic company is taking a risk in launching the drug.

Bristol-Myers and Sanofi-Aventis sued Apotex over plans to launch a generic version before agreeing to the deal, which is now under federal criminal investigation.

Apotex reiterated Tuesday that its version of Plavix doesn't infringe on the drug patent because the patent is invalid.

But if a court finds there is infringement, Apotex will have to pay damages to Bristol-Myers and Sanofi-Aventis.

Typically, the damages would amount to three times the patent holder's lost profits. But under the terms of the deal,

PATENT DISPUTE; Drug fight escalates; Bristol-Myers shares slip after rival launches generic version of blood thinner The Houston Chronicle August 9, 2006 Wednesday

Apotex will only have to pay either 40 percent or 50 percent of its sales to the brand-name makers if a court finds it infringed on the patent.

Experts say the deal reduces the risk of the generic launch, calling into question the brand-name makers' judgment.

"That was a big strategic mistake," said Albert Rauch, an analyst at AG Edwards & Sons, who downgraded Bristol-Myers shares to a sell.

Rauch said the deal raises questions about Bristol-Myers Chief Executive Peter Dolan, who has been at the helm of the company during a major accounting scandal and a problematic investment in biotech company ImClone Systems.

In the filing on Tuesday, Bristol-Myers said Dolan had been subpoenaed in the criminal inquiry in the Apotex deal.

GRAPHIC: Photos: 1. SINKING SHARES: Specialist Richard Plum, center, conducts trading in shares of Bristol-Myers Squibb Co., which fell nearly 7 percent Tuesday at the New York Stock Exchange. Apotex Corp.'s version of the company's best-selling drug, Plavix, is expected to be available to the public today.; 2. DRUG ISSUES: Blood thinner Plavix is the subject of a patent disagreement between drug companies.

1. RICHARD DREW : ASSOCIATED PRESS, 2. MARK LENNIHAN : AP

LOAD-DATE: August 9, 2006

EXHIBIT V

1 of 1 DOCUMENT

Copyright 2006 The New York Times Company
The New York Times

August 9, 2006 Wednesday
Late Edition - Final

SECTION: Section C; Column 6; Business/Financial Desk; Pg. 1

LENGTH: 1533 words

HEADLINE: Marketers Of Plavix Outfoxed On a Deal

BYLINE: By STEPHANIE SAUL

BODY:

The generic drug maker Apotex yesterday began shipping a cheaper form of Plavix, the anticlotting agent that is one of the world's best-selling drugs, in an embarrassing setback for the drug's brand-name marketers, Sanofi-Aventis and Bristol-Myers Squibb.

A year ago, analysts had predicted that the companies had a better than 60 percent chance of winning a patent dispute with Apotex. But an attempt by the companies to settle the dispute has backfired, opening the way for Apotex to enter the market.

"It looks like a much smaller generic private company completely outmaneuvered two of the giants of the pharmaceutical industry," said Gbola Amusa, European pharmaceutical analyst for Sanford C. Bernstein & Company. "It's not clear how or why that happened. The reaction from investors and analysts has ranged from shock to outright anger."

The generic version, called clopidogrel, is expected to be available in the United States beginning today at prices about 30 percent below the \$4-a-day retail price for Plavix. The drug, used for preventing heart attacks and strokes, had sales of more than \$6 billion last year.

Shares of Bristol-Myers, which gets nearly one-fifth of its revenue from Plavix, were down 6.85 percent yesterday on the prospect of a major erosion of those sales. The American depository receipts of Sanofi, a French company that sells Plavix outside the United States, were off by nearly 1 percent.

Barry Sherman, Apotex's chief executive, predicted that clopidogrel, the biggest-selling drug ever to go generic, would mark the "largest and most successful launch" of a generic drug in history. Apotex's move into the market follows the government's recent rejection of the proposed patent settlement, which Bristol-Myers and Sanofi had hoped would keep the generic drug off the market until 2011.

Despite the government's rejection of the deal, some terms of that agreement remain in effect. And they hold at least two significant disadvantages for Bristol and Sanofi. Under the terms, the companies must wait five business days before seeking a federal injunction against Apotex's shipments, giving the generic company an opportunity to potentially flood the market with its generic drug before a court can step in.

The big companies also negotiated away their rights under federal law to seek triple financial damages if they

Marketers Of Plavix Outfoxed On a Deal The New York Times August 9, 2006 Wednesday

eventually win the patent dispute in court. That proviso removed one of the major deterrents to a generic competitor's entering the market while a drug is still under patent.

Analysts said the developments raised doubts about the leadership of Bristol-Myers and Sanofi and the wisdom of the concessions they had made to Apotex. And because the abortive patent settlement is also now the subject of a federal criminal inquiry, some analysts raised questions about whether Peter R. Dolan, Bristol-Myers's chief executive, can survive.

"On the surface, it doesn't look good," said Jami Rubin, a Morgan Stanley analyst. "Credibility, I think, has been severely set back."

In a letter to employees yesterday, Mr. Dolan warned that there would be negative news accounts of the generic introduction, but he defended the company's efforts to protect its intellectual property rights.

A Bristol-Myers spokesman, Tony Plohoros, said the company was evaluating its legal and commercial options. Those could include a decision by the company to drastically lower the price of Plavix or to introduce its own generic equivalent.

In a statement, the French company Sanofi said it was also evaluating possible remedies against Apotex, which a lawyer for Bristol-Myers accused in court of intentionally sabotaging the deal.

Mr. Sherman, in a telephone interview, all but ridiculed his two big rivals, saying they had naively agreed to conditions that allowed his company to bring its product to market even though the deal was rejected by regulators.

"I think they acted foolishly in a number of ways," said Mr. Sherman, a Toronto billionaire who amassed his fortune in the generic drug business.

Mr. Sherman said that he had never expected the American government to approve the deal, but that he had conducted the negotiations in a way to let him push the Apotex drug onto the market.

Mr. Sherman said Apotex was engaged in an "all-out launch" and has already shipped most of its inventory while manufacturing continues.

Some analysts predicted yesterday that by the time a federal judge in New York could rule on the big companies' request to block the drug's sale, based on their patent that runs until late 2011, Apotex could have up to \$1 billion of its product on the market. The decision could take weeks, analysts said.

Jennifer Luddy, a spokeswoman for Medco Health Solutions, which operates employee-sponsored prescription drug plans, said it would begin sending the drug today to customers who receive mail-order Plavix unless their doctor specified the brand-name drug.

The advent of generic Plavix raises questions among analysts as to whether Bristol-Myers will be forced to cut its hefty dividend of \$1.12 a year, or 5.28 percent. Mr. Plohoros declined to predict yesterday.

Shares of Bristol-Myers fell \$1.56, to \$21.21. The stock is now down 18 percent since the company disclosed last month that the Apotex deal was the target of a Justice Department investigation.

American depository receipts of Sanofi fell 44 cents, to \$44.45.

As part of the federal investigation, the F.B.I. recently searched the offices of Mr. Dolan and Dr. Andrew Bodnar, his close adviser. Dr. Bodnar visited Mr. Sherman's Toronto office twice to personally negotiate part of the deal, according to Mr. Sherman.

Marketers Of Plavix Outfoxed On a Deal The New York Times August 9, 2006 Wednesday

The Justice Department is believed to be investigating whether Bristol and Sanofi tried to conceal a so-called side deal with Apotex that would not have passed regulatory muster. Both companies have denied doing anything improper.

"Bodnar kept saying that he was in contact with Peter Dolan and Dolan was 100 percent behind whatever he was negotiating," Mr. Sherman said yesterday. "Whatever he was doing, whether or not there were side deals that were not reported to the F.T.C, I cannot comment on."

The one-on-one negotiations between Mr. Sherman and Dr. Bodnar, and the search of Bristol-Myers's corporate offices on July 26, were elements of the corporate intrigue discussed in court transcripts that were unsealed yesterday by United States District Judge Sidney H. Stein in New York. Judge Stein is overseeing the patent dispute, which is now expected to go to trial next year.

In the transcripts of discussions that have taken place before the judge during the past week, a lawyer for Bristol-Myers accused Apotex of generating the criminal investigation -- and thereby sabotaging the deal -- by providing false information to the federal government.

"The best evidence we have, the best information we have, is that that occurred as a result of something that Apotex said to the government, which we believe to be untrue," Evan Chesler, a lawyer for Bristol-Myers, said during the court proceedings.

In the telephone interview yesterday, Mr. Sherman declined to comment on what Apotex had or had not told the government. But he said he never expected the deal to clear regulatory review and went along with it simply to position his company to enter the market with its generic. Mr. Sherman said he viewed efforts by brand-name companies to extend monopolies through settlement negotiations as "outrageous."

"Our focus was to get the concession that would enable us to launch, when the F.T.C. turned us down," Mr. Sherman said.

The decision by Apotex to sell generic Plavix follows several years of patent litigation among the companies. In January, with that litigation continuing, the Food and Drug Administration approved Apotex's formulation of generic Plavix.

In March, the parties announced they had reached an agreement. Apotex was given the right to sell the generic drug in September 2011, several months before the patent was set to expire, and Bristol-Myers and Sanofi agreed to pay the company \$40 million. The bigger companies also agreed not to issue their own generic version until six months after Apotex began marketing it.

The agreement was revised after objections by antitrust regulators, including state attorneys general and the Federal Trade Commission. Notably, the revised agreement that was submitted to regulators allowed Apotex to begin marketing in June 2011 and omitted the provision that Bristol-Myers and Sanofi would not market their own generic during the first six months Apotex was on the market.

The two big companies also agreed to honor the concessions -- the five-day delay in a request for an injunction and the waiver of triple damages -- even if the government rejected the deal. "They were so intent on extending their monopoly out for five years and ultimately blind to the idea" that government officials would turn it down, Mr. Sherman said.

"What they should have done, if they were smart," he said, "they should have said, 'We'll stand on our rights. We'll fight in court.' That's what they should have said."

URL: <http://www.nytimes.com>

Marketers Of Plavix Outfoxed On a Deal The New York Times August 9, 2006 Wednesday

LOAD-DATE: August 9, 2006

EXHIBIT W

APPEAL, SUSPENSE

U.S. District Court
United States District Court for the Southern District of New York (Foley Square)
CIVIL DOCKET FOR CASE #: 1:02-cv-02255-SHS

Sanofi-Synthelabo, et al v. Apotex Inc., et al
Assigned to: Judge Sidney H. Stein
Demand: \$0
Case in other court: US Courts of Appeal for the Federal
Circuit, 07-01438
Cause: 35:271 Patent Infringement

Date Filed: 03/21/2002
Jury Demand: Plaintiff
Nature of Suit: 830 Patent
Jurisdiction: Federal Question

Plaintiff**Sanofi-Synthelabo**

represented by **David Noah Greenwald**
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
(212) 474-1000
Fax: (212) 474-3700
Email: dgreenwald@cravath.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Evan R Chesler
Cravath Swaine Moore LLP
825 8th Avenue
New York, NY 10019
(212) 474-1000
LEAD ATTORNEY

Richard J Stark
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
(212) 474-1000
Fax: (212) 474-3700
Email: rstark@cravath.com
LEAD ATTORNEY

Robert L. Baechtold
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112
(212) 218-2100
LEAD ATTORNEY

Thomas H. Beck

Sidley Austin LLP(NY)
787 Seventh Avenue
New York, NY 10019
212-839-5940
Fax: 212-839-5599
Email: tbeck@sidley.com
LEAD ATTORNEY

William Ericson Solander
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112-3801
(212) 218-2100
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

John D. Murnane
Fitzpatrick Cella Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112-3801
(212) 218-2100
Fax: (212) 218-2200
ATTORNEY TO BE NOTICED

Plaintiff

Sanofi-Synthelabo Inc.

represented by **David Noah Greenwald**
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Evan R Chesler
(See above for address)
LEAD ATTORNEY

John D. Murnane
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Richard J Stark
(See above for address)
LEAD ATTORNEY

Robert L. Baechtold
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

William Ericson Solander
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Plaintiff

**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

represented by **David Noah Greenwald**
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Evan R Chesler
(See above for address)
LEAD ATTORNEY

John D. Murnane
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Richard J Stark
(See above for address)
LEAD ATTORNEY

Robert L. Baechtold
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

William Ericson Solander
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

V.

Defendant

Apotex Inc.

represented by **Allan H. Fried**
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street
12th Floor
Philadelphia, PA 19103
LEAD ATTORNEY

Anthony F Lo Cicero

Amster, Rothstein & Ebenstein LLC
90 Park Avenue
New York, NY 10016
212-336-8810
Fax: 212-336-8001
Email: alocicero@arelaw.com
TERMINATED: 02/10/2006
LEAD ATTORNEY

Bruce J. Chasan
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street-12th Floor
Seven Penn Center
Philadelphia, PA 19103-2212
(215) 567-2010
LEAD ATTORNEY

Karen J. Bernstein
Pryor Cashman Sherman & Fynn LLP
410 Park Avenue
New York, NY 10022
212-326-0472
TERMINATED: 10/24/2006
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Karen Jill Bernstein
Amster, Rothstein & Ebenstein LLC
90 Park Avenue
New York, NY 10016
212-336-8123
Fax: 212 336-8001
Email: kjbernstein@arelaw.com
TERMINATED: 10/24/2006
LEAD ATTORNEY

Kevin A. Keeling
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street, 11th Floor
Philadelphia, PA 19103
(215)-567-2010
Fax: 215)-751-1142
Email: kkeeling@crbcp.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Manny D. Pokotilow
Caesar, Rivise, Bernstein, Cohen &

Pokotilow, Ltd.
7 Penn Center
1635 Market Street
Philadelphia, PA 19103
(215) 567-2010
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Mona Gupta
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street
12th Floor
Philadelphia, PA 19103
LEAD ATTORNEY

Robert S. Silver
Caesar, Rivise, Bernstein, et al
1635 Market Street
11th Floor
Philadelphia, PA 19103-2212
(215) 567-2010
Fax: (215) 751-1142
LEAD ATTORNEY

William J. Castillo
Caesar, Rivise, Bernstein, et al
1635 Market Street
11th Floor
Philadelphia, PA 19103-2212
(215) 567-2010
Fax: (215) 751-1142
LEAD ATTORNEY

William C. Youngblood
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street
11th Floor
Philadelphia, PA 10016
(215) 567-2010
Fax: (215) 751-1142
LEAD ATTORNEY

James Kozuch
Cesar, Rivise, Bernstein Cohen &
Pokotiluw
1635 Market Street
11th Floor
Philadelphia, PA 19103

(215) 567-2010
ATTORNEY TO BE NOTICED

Robert Burton Breisblatt
Harwood Feffer, LLP
488 Madison Avenue
8th Floor
New York, NY 10022

Defendant

Apotex Corp.

represented by **Allan H. Fried**
(See above for address)
LEAD ATTORNEY

Anthony F Lo Cicero
(See above for address)
TERMINATED: 02/10/2006
LEAD ATTORNEY

Bruce J. Chasan
(See above for address)
LEAD ATTORNEY

Karen J. Bernstein
(See above for address)
TERMINATED: 10/24/2006
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Karen Jill Bernstein
(See above for address)
TERMINATED: 10/24/2006
LEAD ATTORNEY

Kevin A. Keeling
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Manny D. Pokotilow
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Mona Gupta
(See above for address)
LEAD ATTORNEY

Robert S. Silver
(See above for address)

LEAD ATTORNEY

William J. Castillo
(See above for address)
LEAD ATTORNEY

William C. Youngblood
(See above for address)
LEAD ATTORNEY

James Kozuch
(See above for address)
ATTORNEY TO BE NOTICED

Robert Burton Breisblatt
(See above for address)

Defendant

Dr. Reddy's Laboratories, Ltd.

Defendant

Dr. Reddy's Laboratories, Inc.

Amicus

**National Association of Chain Drug
Stores**

represented by **Zachary R. Davis**
Hangley Aronchick Segal & Pudlin
One Logan Square, 27th Floor
Philadelphia, PA 19103
215-496-7042
Fax: 215-568-0300
Email: zdavis@hangley.com
ATTORNEY TO BE NOTICED

Counter Claimant

Apotex Inc.

represented by **Anthony F Lo Cicero**
(See above for address)
TERMINATED: 02/10/2006
LEAD ATTORNEY

Bruce J. Chasan
(See above for address)
ATTORNEY TO BE NOTICED

Mona Gupta
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street
Philadelphia, PA 19103
ATTORNEY TO BE NOTICED

Counter Claimant**Apotex Corp.**

represented by **Anthony F Lo Cicero**
(See above for address)
TERMINATED: 02/10/2006
LEAD ATTORNEY

Bruce J. Chasan
(See above for address)
ATTORNEY TO BE NOTICED

Mona Gupta
(See above for address)
ATTORNEY TO BE NOTICED

V.

Counter Defendant**Sanofi-Synthelabo**

represented by **Evan R Chesler**
(See above for address)
LEAD ATTORNEY

Richard J Stark
(See above for address)
LEAD ATTORNEY

Robert L. Baechtold
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

Counter Defendant**Sanofi-Synthelabo Inc.**

represented by **Evan R Chesler**
(See above for address)
LEAD ATTORNEY

Richard J Stark
(See above for address)
LEAD ATTORNEY

Robert L. Baechtold
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

Counter Defendant**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**represented by **Evan R Chesler**
(See above for address)
*LEAD ATTORNEY***Richard J Stark**
(See above for address)
*LEAD ATTORNEY***Robert L. Baechtold**
(See above for address)
*LEAD ATTORNEY***Thomas H. Beck**
(See above for address)
*LEAD ATTORNEY***Counter Claimant****Apotex Inc.**represented by **Bruce J. Chasan**
(See above for address)
*ATTORNEY TO BE NOTICED***Mona Gupta**
(See above for address)
*ATTORNEY TO BE NOTICED***Counter Claimant****Apotex Corp.**represented by **Bruce J. Chasan**
(See above for address)
*ATTORNEY TO BE NOTICED***Mona Gupta**
(See above for address)
ATTORNEY TO BE NOTICED

V.

Counter Defendant**Sanofi-Synthelabo****Counter Defendant****Sanofi-Synthelabo Inc.****Counter Defendant****Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

--	--	--

Date Filed	#	Docket Text
03/21/2002	1	COMPLAINT filed. Summons issued and Notice pursuant to 28 U.S.C. 636(c). FILING FEE \$ 150.00 RECEIPT # 434089. (jol) (Entered: 03/22/2002)
03/21/2002		Magistrate Judge Ronald L. Ellis is so designated. (jol) (Entered: 03/22/2002)
03/21/2002	2	RULE 1.9 CERTIFICATE filed by Sanofi-Synthelabo . (jol) (Entered: 03/22/2002)
03/21/2002	3	RULE 1.9 CERTIFICATE filed by Synthelabo Inc. . (jol) (Entered: 03/22/2002)
03/21/2002	4	RULE 1.9 CERTIFICATE filed by Bristol-Myers Squibb . (jol) (Entered: 03/22/2002)
03/22/2002		Mailed notice to Commissioner of Patents and Trademarks to report the filing of this action. (jol) (Entered: 03/22/2002)
04/05/2002	7	DEMAND for jury trial by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb . (bai) (Entered: 04/29/2002)
04/09/2002	5	RULE 1.9 CERTIFICATE filed by Apotex Inc., Apotex Corp. (moc) (Entered: 04/18/2002)
04/09/2002	6	ANSWER to Complaint and COUNTERCLAIM by Apotex Inc., Apotex Corp. (Attorney Anthony F. Lo Cicero) against Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb ; Firm of: Amster, Rothstein & Ebenstein by attorney Anthony F. Lo Cicero for defendant Apotex Corp. (moc) (Entered: 04/18/2002)
04/25/2002	7	REPLY by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb to [6-2] counter claim ; Firm of: Fitzpatrick, Cella, Harper & Scinto by attorney Robert L. Baechtold for counter-defendant Bristol-Myers Squibb (bai) (Entered: 04/29/2002)
05/10/2002	8	NOTICE OF MOTION by Apotex Inc., Apotex Corp.; for an Order pursuant to F.R.C.P. 12(f), striking plaintiffs' demand for jury trial . Return Date 6/19/02 at 12:00. (jco) (Entered: 05/15/2002)
05/10/2002	9	NOTICE OF MOTION by Apotex Inc., Apotex Corp.; for an Order granting Alan H. Bernstein to appear pro hac vice ; for Robert S. Silver to appear pro hac vice . Return Date not indicated. (jco) (Entered: 05/15/2002)
05/10/2002	10	MEMORANDUM OF LAW by Apotex Inc., Apotex Corp. in support of [8-1] motion for an Order pursuant to F.R.C.P. 12(f), striking plaintiffs' demand for jury trial. (jco) (Entered: 05/15/2002)
05/10/2002	11	DECLARATION of Anthony F. Lo Cicero by Apotex Inc., Apotex Corp. in support Re: [9-1] motion for an Order granting Alan H. Bernstein to appear pro hac vice, [9-2] motion for Robert S. Silver to appear pro hac vice. (jco) (Entered: 05/15/2002)

05/24/2002	12	BRIEF by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb in opposition to [8-1] motion for an Order pursuant to F.R.C.P. 12(f), striking plaintiffs' demand for jury trial (db) (Entered: 05/28/2002)
06/03/2002	13	REPLY MEMORANDUM by Apotex Inc., Apotex Corp. in support of [8-1] motion for an Order pursuant to F.R.C.P. 12(f), striking plaintiffs' demand for jury trial (sac) (Entered: 06/11/2002)
06/13/2002	14	STIPULATION and ORDER; consolidating this action with action # 02 cv 3672 for discovery and pretrial purposes. Consolidation for trial may be considered at a later date; the hearing scheduled for 6/12/02 is cancelled . (signed by Judge Robert W. Sweet) (jp) (Entered: 06/16/2002)
06/14/2002		Memo endorsed on motion; granting [9-1] motion for an Order granting Alan H. Bernstein to appear pro hac vice, granting [9-2] motion for Robert S. Silver to appear pro hac vice . (signed by Judge Robert W. Sweet); Copies mailed. Document sent to Attorney Admissions Clerk. (jp) (Entered: 06/18/2002)
06/25/2002	15	JOINT FEDERAL RULE OF CIVIL PROCEDURE 26(F) REPORT; that in accordance with Rule 26(f) of the F.R.C.P., the parties have conferred and respectfully submit this Joint Rule 26(f) Report . (signed by Judge Robert W. Sweet); Copies mailed. (pl) (Entered: 06/27/2002)
06/26/2002	16	Joint F.R.C.P. 26(f) Report by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb, Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb . (dle) (Entered: 07/09/2002)
08/19/2002	17	Letter filed by Apotex Inc. addressed to Judge Robert W. Sweet from Anthony F. LoCicero, dated 7/30/02, re: Apotex's motion to strike dated 5/10/02. (dle) (Entered: 08/22/2002)
08/19/2002	18	Letter filed by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb addressed to Judge Robert W. Sweet from Robert L. Baechtold, dated 8/8/02, re: 7/30/02 letter sent by Apotex. (dle) (Entered: 08/22/2002)
08/19/2002	19	Letter filed by Apotex Inc., Apotex Corp. addressed to Judge Robert W. Sweet from Anthony F. Lo Cicero, dated 8/9/02, re: plaintiff counsel's 8/8/02 letter. (dle) (Entered: 08/22/2002)
08/20/2002	20	OPINION #87310, granting [8-1] motion for an Order pursuant to F.R.C.P. 12(f), striking plaintiffs' demand for jury trial; Sanofi has leave to file a motion to amend its complaint to include a jury demand prior to trial if damages should be incurred as discussed within this Order . (signed by Judge Robert W. Sweet); Copies mailed. (pl) (Entered: 08/22/2002)
09/26/2002	21	SEALED DOCUMENT placed in vault. (js) (Entered: 09/26/2002)
10/18/2002	22	NOTICE OF MOTION by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb for an order purs. to Rule 37 of the FRCP, compelling dfts Apotex Inc. and Apotex Corp. to produce all improperly withheld

		documents within fourteen (14) days and to provide substantive revised responses to plttfs' interrogatories within five (5) days . Proposed order attached. No Return Date indicated. (db) (Entered: 10/23/2002)
10/18/2002	23	MEMORANDUM OF LAW by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb in support of [22-1] motion for an order purs. to Rule 37 of the FRCP, compelling dfts Apotex Inc. and Apotex Corp. to produce all improperly withheld documents within fourteen (14) days and to provide substantive revised responses to plttfs' interrogatories within five (5) days . (db) (Entered: 10/23/2002)
10/28/2002	24	MEMORANDUM OF LAW by Apotex Inc., Apotex Corp. in opposition to [22-1] motion for an order purs. to Rule 37 of the FRCP, compelling dfts Apotex Inc. and Apotex Corp. to produce all improperly withheld documents within fourteen (14) days and to provide substantive revised responses to plttfs' interrogatories within five (5) days, and substantively respond to plaintiffs' discovery requests. (pl) (Entered: 10/31/2002)
10/31/2002	25	NOTICE OF MOTION by Apotex Inc., Apotex Corp. to compel plntfs to make proper document production and to respond to defts' requests for admission and interrogatories ; Return Date 11/13/02 at 12:00. (cd) (Entered: 11/04/2002)
10/31/2002	26	MEMORANDUM OF LAW by Apotex Inc., Apotex Corp. in support of [25-1] motion to compel plntfs to make proper document production and to respond to defts' requests for admission and interrogatories . (cd) (Entered: 11/04/2002)
11/07/2002	28	REPLY by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb in support of [22-1] motion for an order purs. to Rule 37 of the FRCP, compelling dfts Apotex Inc. and Apotex Corp. to produce all improperly withheld documents within fourteen (14) days and to provide substantive revised responses to plttfs' interrogatories within five (5) days and in opposition to dfts motion to compel documents, interrogatories and admissions. Received in night deposit box on 11/7/02 at 7:17 p.m. (db) Modified on 11/13/2002 (Entered: 11/13/2002)
11/12/2002	27	REPLY MEMORANDUM by Apotex Inc., Apotex Corp. in support of [25-1] motion to compel plntfs to make proper document production and to respond to defts' requests for admission and interrogatories. (sb) (Entered: 11/13/2002)
11/22/2002	29	ORDER, That the parties shall complete all discovery, inspection and motions by 6/30/03, after which no discovery will be conducted and no motion will be entertained without showing of special circumstances showing of special circumstances; The parties shall submit to the Court trial briefs, a joint proposed pretrial order, and, if applicable, proposed jury charges and voir dire requests in accordance with the annexed form and instructions by 7/8/03; A final pretrial conference will be held at 4:30 p.m. on 7/8/03 and the action shall be added to the trial calendar published in the New York Law Journal . (signed by Judge Robert W. Sweet). (tp) (Entered: 11/26/2002)

12/11/2002	32	NOTICE OF MOTION by Apotex Inc., and Apotex Corp. for Bruce J. Chasan to appear pro hac vice . No Return Date. Declaration of William J. Castillo in support is attached. (kw) (Entered: 12/17/2002)
12/11/2002	33	Memo-Endorsement on letter addressed to Clerk of Court from David L. Siberman, dated 12/3/02. Re: granting [32-1] motion for Bruce J. Chasan to appear pro hac vice. No opposition. (signed by Judge Robert W. Sweet); (kw) (Entered: 12/17/2002)
12/13/2002	36	ORDER, that the Court is granting the [32-1] motion for Bruce J. Chasan to appear pro hac vice. (signed by Judge Robert W. Sweet). FORWARDED DOCUMENT TO ATTORNEY ADMISSIONS CLERK. (tp) Modified on 12/26/2002 (Entered: 12/26/2002)
12/16/2002	34	SCHEDULING ORDER: All Discovery, inspection and motions cutoff 8/29/03; Court trial briefs, joint Pretrial order, and if applicable, proposed jury charges and voir dire requests in accordance with the annexed form and instructions by 9/9/03; Pretrial conference set for 9/9/03 (signed by Judge Robert W. Sweet); (cd) (Entered: 12/18/2002)
12/16/2002	35	STIPULATION and ORDER, Completion of Fact Discovery 8/29/03 , Fact Depositions Begin 2/15/03 , Completion of Document Production to be completed by 2/1/03; Plaintiffs to Provide List of Asserted Claims to Defendants 6/9/03; Exchange Contention Interrogatories 6/16/03; Exchange Responses to Contention Interrogatories 7/16/03; Exchange Rebuttal Contention Interrogatories 7/23/03; Exchange Responses to Rebuttal Contention Interrogatories 8/22/03 . signed by Judge Robert W. Sweet) (yv) (Entered: 12/18/2002)
12/31/2002	37	Transcript of record of proceedings before Judge Robert W. Sweet for the date(s) of 11/13/02. (dt) (Entered: 01/02/2003)
12/31/2002	38	Transcript of record of proceedings before Judge Robert W. Sweet for the date(s) of 11/13/02. (dt) (Entered: 01/02/2003)
01/28/2003	39	Memo-Endorsement on letter addressed to Judge Sweet from William E. Solander, dated 01/24/03; counsel to plaintiffs are granted a 27-day extension of time to produce documents in this litigation ; (signed by Judge Robert W. Sweet); (dj) (Entered: 01/31/2003)
01/31/2003	40	Memo-Endorsement on letter addressed to Judge Sweet from William E. Solander, dated 1/30/03. Reset plaintiffs' response to request for production of documents due for 2/28/03 ; reset the start date of depositions to 3/3/03. Denying Dr. Reddy's unrelated requests . (signed by Judge Robert W. Sweet); (kw) (Entered: 02/07/2003)
02/07/2003	41	SEALED DOCUMENT placed in vault. (wv) (Entered: 02/07/2003)
02/21/2003	42	AMENDED ANSWER to Complaint by Apotex Inc., Apotex Corp. : amends [6-1] answer. (moc) (Entered: 02/25/2003)
03/07/2003	43	REPLY by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb to Amended Counterclaims; by attorney Robert L. Baechtold for counter-defendant Bristol-Myers Squibb, Thomas H. Beck for counter-defendant

		Bristol-Myers Squibb, Evan R. Chesler for counter-defendant Bristol-Myers Squibb, Richard J. Stark counter-defendant Bristol-Myers Squibb (cd) (Entered: 03/10/2003)
04/03/2003	44	STIPULATION and ORDER, regarding procedures that will govern the handling of confidential information (signed by Judge Robert W. Sweet); also docketed in 02 cv 3672 (cd) (Entered: 04/04/2003)
04/23/2003	45	NOTICE OF MOTION by Apotex Inc., Apotex Corp. for an order granting defendants' motion for admission pro hac vice of Allan H. Fried on behalf of Apotex Inc. and Apotex Corp. . No Return Date. (sb) (Entered: 04/24/2003)
04/23/2003	46	DECLARATION of Karen J. Bernstein by Apotex Inc., Apotex Corp. in support of [45-1] motion for an order granting defendants' motion for admission pro hac vice of Allan H. Fried on behalf of Apotex Inc. and Apotex Corp. (sb) (Entered: 04/24/2003)
05/01/2003	47	ORDER, granting [45-1] motion for an order granting defendants' motion for admission pro hac vice of Allan H. Fried on behalf of Apotex Inc. and Apotex Corp. (signed by Judge Robert W. Sweet); (Sent to the Attorney Admissions Clerk). (kw) (Entered: 05/02/2003)
06/24/2003	48	STIPULATION and ORDER, Purs to Rule 41(a)(1)(ii) of the FRCP, Plaintiffs' Complaint of patent infringement with respect to United States Patent No. 5,576,328 shall be and hereby is, dismissed with prejudice. Purs to Rule 41(c) of the FRCP, Counts 1, IV and V of the Apotex's Amended Answer to the Complaint for Patent Infrngement Affirmative Defenses and Amended Counterclaims shall be and hereby are, dismissed with prejudice. Sanofi will not assert the '328 patent against Apotex on the basis of Apotex's present Abbreviated New Drug Application No. 76-274, including any minor amendments thereto, or on the basis of the sale, offer for sale, manufacture, import, export or use of the product which is the subject of ANDA NO. 76-274 ; (signed by Judge Robert W. Sweet) (dj) (Entered: 06/24/2003)
06/26/2003	49	STIPULATION AND ORDER; purs. to Rule 41(a)(1)(ii) of the FRCP, Pltffs' Complaint for patent infringement with respect to U.S. Patent No. 5,576,328 shall be dismissed with prejudice. Purs. to Rule 41(c) of the FRCP, Counts I, IV and V of Apotex's Amended Answer to Complaint for Patent Infringement Affirmative Defenses and Amended Counterclaims shall be and hereby are, dismissed with prejudice. (signed by Judge Robert W. Sweet) (sac) (Entered: 06/27/2003)
07/14/2003	50	Memo-Endorsement on letter addressed to Judge Sweet from Robert L. Baechtold, dated 7/2/03: Granting plaintiffs' request for clarification of the Court's 12/12 and 12/13/02 Scheduling Orders ; Granting plaintiffs' request to vacate the 12/13/02 Scheduling Order . (signed by Judge Robert W. Sweet); (tp) (Entered: 07/14/2003)
08/21/2003	51	NOTICE OF MOTION by Apotex Inc., Apotex Corp. for an order admitting Mona Gupta to appear pro hac vice for defendants . No Return Date. (sb) (Entered: 08/25/2003)

08/21/2003	52	DECLARATION of Karen J. Bernstein by Apotex Inc., Apotex Corp. in support of [51-1] motion for an order admitting Mona Gupta to appear pro hac vice for defendants. (sb) (Entered: 08/25/2003)
08/26/2003	53	STIPULATION and ORDER, that the parties stipulate, subject to the consent of the Court, to the pre-trial schedule set forth herein: Completion of fact discovery is 10/15/03; All other deadlines are set accordingly . (signed by Judge Robert W. Sweet) (tp) (Entered: 08/27/2003)
09/04/2003	54	ORDER; granting [51-1] motion for an order admitting Mona Gupta to appear pro hac vice for defendants. (signed by Judge Robert W. Sweet); Forwarded to attorney admissions clerk. (jco) (Entered: 09/08/2003)
09/30/2003		Terminated documents 22-1, 25-1 pursuant to instructions of Judge Sweet as indicated on the CJRA report. (rag) (Entered: 10/03/2003)
10/08/2003	55	SECOND AMENDED ANSWER to Complaint by Apotex Inc., Apotex Corp.: amends [42-1] answer to the complaint for patent infringement affirmative defenses and amended counterclaims. (jco) (Entered: 10/09/2003)
10/10/2003	56	SEALED DOCUMENT placed in vault. (kre) Modified on 10/14/2003 (Entered: 10/14/2003)
10/15/2003	57	SEALED DOCUMENT placed in vault. (wv) Modified on 10/16/2003 (Entered: 10/16/2003)
10/21/2003	58	SEALED DOCUMENT placed in vault. (wv) (Entered: 10/22/2003)
10/23/2003	59	REPLY by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb to second amended counterclaims; Firm of: Fitzpatrick, Cella, Harper & Scinto by attorney Robert L. Baechtold for counter-defendant Bristol-Myers Squibb, Thomas H. Beck for counter-defendant Bristol-Myers Squibb, Evan R. Chesler for counter-defendant Bristol-Myers Squibb, Richard J. Stark for counter-defendant Bristol-Myers Squibb. Received in night deposit box on 10/23/03 at 6:50 p.m. (yv) Modified on 10/28/2003 (Entered: 10/28/2003)
10/27/2003	60	SEALED DOCUMENT placed in vault. (wv) (Entered: 10/28/2003)
10/31/2003	61	ADDENDUM TO STIPULATED PROTECTIVE ORDER: subject to the approval of the Court, should any party to this action seek discovery from a non-party, the non party may designate documents in the non-partys possession in accordance with the provisions of the Stipulated Protective Order entered in this civil action and the parties shall treat designated documents in the same manner as documents designated by the parties to this action . (signed by Judge Robert W. Sweet) (db) (Entered: 11/04/2003)
10/31/2003	64	Letter filed by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb addressed to Judge Sweet from Thomas H. Beck, dated 10/14/03, re: plttfs reply to Reddy 10/14/03 response. (db) (Entered: 11/04/2003)

10/31/2003	66	Letter filed by Sanofi-Synthelabo, Synthelabo Inc., Bristol-Myers Squibb addressed to Judge Sweet from Thomas H. Beck, dated 10/21/03, re: response to dfts 10/17/03 letter. (db) (Entered: 11/04/2003)
11/04/2003	69	ORDER, defendants, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. produce 10 grams of their bulk clopidogrel bisulfate product and 10 of their clopidogrel bisulfate tablets to plaintiffs within 21 days from 10/29/03, namely on 11/19/03, to be delivered to the New York Offices of Fitzpatrick, Cella, Harper & Scinto and, the schedule ordered by the Court on 8/21/03 shall be adhered to by all parties . (signed by Judge Robert W. Sweet); (yv) (Entered: 11/06/2003)
11/14/2003	70	REDDY's OPENING CLAIM CONSTRUCTION BRIEF. (sb) (Entered: 11/19/2003)
11/14/2003	71	Apotex Corp. and Apotex, Inc.'s Opening Claim Construction Brief. (sb) (Entered: 11/19/2003)
12/01/2003	72	ENDORSED LETTER addressed to Judge Robert W. Sweet from Louis Weinstein dated 11/24/03 re: Counsel for Reddy dfts request deposition. Motion granted. Deposition to be taken at counsel's convenience in January. File the defendants brief 10 days thereafter. (Signed by Judge Robert W. Sweet on 11/26/03) (Lewis, Diahann) (Entered: 12/09/2003)
01/28/2004	76	OPINION # 89616: for reasons further set forth in said Opinion, the attorney-client privilege has been FORFEITED. Settle order on notice. (Signed by Judge Robert W. Sweet on 1/26/04) (db,) (Entered: 02/03/2004)
01/29/2004	77	PLAINTIFFS' RESPONSIVE BRIEF in support of Plaintiffs' proposed construction of claim 3. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo and Sanofi-Synthelabo Inc. Received in the night deposit box on 1/29/04 at 6:25 p.m. (sb,) (Entered: 02/04/2004)
01/29/2004	78	RESPONSIVE CLAIM CONSTRUCTION BRIEF. Document filed by Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (sb,) (Entered: 02/09/2004)
02/11/2004	81	MOTION for Reconsideration re; [76] Memorandum & Opinion. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelabo Inc. Oral Argument requested. Received in night deposit box on 2/11/04 at 11:24 p.m. (db,) (Entered: 02/17/2004)
02/25/2004	84	NOTICE OF CASE REASSIGNMENT to Judge Sidney H. Stein. Judge Robert W. Sweet no longer assigned to the case. (gf,) (Entered: 02/26/2004)
02/26/2004		Mailed notice to the attorney(s) of record. (gf,) (Entered: 02/26/2004)
05/12/2004	85	STIPULATION AND ORDER; that for the purposes of this litigation, subject to the consent of the Court, that claim 3 of U.S. Patent 4,847,265 has the construction that is set forth in this Stipulation and Order. (Signed

		by Judge Sidney H. Stein on 5/7/04) (pl,) (Entered: 05/13/2004)
05/13/2004	86	ADDENDUM TO STIPULATED PROTECTIVE ORDER; that subject to the approval of the Court, Paragraph 3(a) is amended with respect to the attorneys for dft. Apotex, Inc. and Apotex Corp. to add the following Langer & Grogan, P.C., 1600 Market Street, Suite 2020, Philadelphia, PA 19103-7218. (Signed by Judge Sidney H. Stein on 5/12/04) (pl,) (Entered: 05/14/2004)
08/13/2004	87	STIPULATION AND ORDER; that on consent of the Court, the pretrial schedule is as follows: Completion of document production by 2/1/05; Fact Depositions begin 2/15/03; completion of fact discovery by 10/15/03; Rebuttal to expert reports by 7/14/04; Reply to Expert Reports by 8/30/04; pretrial Order due 30 days after close of expert depositions 12/8/04; additional deadlines are as set forth in this Stipulation and Order. (Signed by Judge Sidney H. Stein on 8/10/04) (pl,) (Entered: 08/17/2004)
09/10/2004	88	MOTION (FILED ON SERVICE DATE) for Leave to File its Third Amended Answer/Counteclaims. Document filed by Apotex Corp. (cd,) (Entered: 09/15/2004)
09/10/2004	89	DECLARATION of Karen Bernstein in Support re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Apotex Corp.. (cd,) (Entered: 09/15/2004)
09/10/2004	90	MEMORANDUM OF LAW in Support re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Apotex Corp.. (cd,) (Entered: 09/15/2004)
09/10/2004	91	REPLY MEMORANDUM OF LAW in Support re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Apotex Corp. (cd,) (Entered: 09/15/2004)
09/10/2004	92	REPLY DECLARATION of Karen Bernstein in Support re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Apotex Corp. (cd,) (Entered: 09/15/2004)
09/21/2004	93	MOTION (FILED ON SERVICE DATE) for Howard Israel Langer and John James Grogan to Appear Pro Hac Vice. Document filed by Apotex Corp., Apotex Inc. (cd,) (Entered: 09/23/2004)
09/21/2004	94	DECLARATION of Karen Bernstein in Support re: [93] MOTION (FILED ON SERVICE DATE) for Howard Israel Langer and John James Grogan to Appear Pro Hac Vice.. Document filed by Apotex Corp., Apotex Inc.. (cd,) (Entered: 09/23/2004)
09/27/2004	95	ORDER granting Apotex's motion for admission pro hac vice of Howard Israel Langer and John James Grogan as co counsel to Apotex Inc. and Apotex Corp in this action. (Signed by Judge Sidney H. Stein on 9/22/04) (dle,) (Entered: 09/28/2004)
09/27/2004		Transmission to Attorney Admissions Clerk. Transmitted re: [95] Order, to the Attorney Admissions Clerk for updating of Attorney Information.

		(dle,) (Entered: 09/28/2004)
12/22/2004	96	AMENDED RULE 7.1 DISCLOSURE STATEMENT. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelabo Inc..(dle,) (Entered: 12/27/2004)
12/22/2004	97	AMENDED RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Synthelabo Inc..(dle,) (Entered: 12/27/2004)
12/22/2004	98	RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Synthelabo.(dle,) (Entered: 12/27/2004)
01/05/2005	99	ORDER: Status Conference set for 1/14/2005 at 2:00 PM before Judge Sidney H. Stein in Courtroom 23A, regarding Motions filed in 02-cv-2255, 02-cv-3672 and 04-cv-7548. (Signed by Judge Sidney H. Stein on 1/3/05) (sac,) (Entered: 01/06/2005)
01/05/2005	100	STIPULATION AND ORDER; expert depositions: beginning 9/27/04 and lasting until 11/18/04; pretrial order: all parties exchange their portions of the Pretrial Order, e.g., exhibit lists, deposition designations, witness lists, etc. by 2/11/05; all parties exchange objections by 2/25/05; plaintiffs submit the Pretrial Order to the Court by 3/4/05. (Signed by Judge Sidney H. Stein on 12/28/04). This Document Relates to: 02civ3672. (sac,) (Entered: 01/06/2005)
01/11/2005	102	OPPOSITION TO PLAINTIFFS' MEMORANDUM OF LAW IN SUPPORT OF ITS MOTION FOR CONSOLIDATION. Document filed by Apotex Inc., Apotex Corp..(pl,) (Entered: 01/20/2005)
01/11/2005	103	DECLARATION of Karen J. Bernstein in Support re: [91] Reply Memorandum of Law in Support of Motion. Document filed by Apotex Inc., Apotex Corp.. (pl,) (Entered: 01/20/2005)
01/11/2005	104	REPLY in support of re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Apotex Inc., Apotex Corp.. (pl,) (Entered: 01/20/2005)
01/11/2005	105	DECLARATION of Karen J. Bernstein in Support of Apotex, Inc. and Apotex Corp.'s opposition to plaintiffs' Memorandum of Law in support of its motion for consolidation. Document filed by Apotex Inc., Apotex Corp.. (pl,) (Entered: 01/20/2005)
01/14/2005	101	THIRD AMENDED ANSWER to Complaint. AMENDED COUNTERCLAIM against Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. Document filed by Apotex Inc., Apotex Corp. (db,) (Entered: 01/19/2005)
01/14/2005	106	MEMORANDUM OF LAW in Opposition re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File. Document filed by Sanofi-Synthelabo. (cd,) (Entered: 01/21/2005)
01/14/2005	108	DECLARATION of Karen Bernstein in Support re: [107] MOTION for Leave to File Third Amended Answer.. Document filed by Apotex Corp..

		(cd,) (Entered: 01/21/2005)
01/14/2005	109	MEMORANDUM OF LAW in Support re: [107] MOTION for Leave to File Third Amended Answer.. Document filed by Apotex Corp.. (cd,) (Entered: 01/21/2005)
01/21/2005	107	MOTION for Leave to File Third Amended Answer. Document filed by Apotex Corp. (cd,) (Entered: 01/21/2005)
01/26/2005	110	TRANSCRIPT of proceedings held on 1/14/05 before Sidney H. Stein. (Martin, Leslie) (Entered: 01/26/2005)
01/31/2005	111	REPLY re: [101] Amended Counterclaim. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (ps,) (Entered: 02/04/2005)
02/09/2005	112	DEMAND for Trial by Jury. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership(pl,) (Entered: 02/16/2005)
02/16/2005	113	STIPULATION AND ORDER: all parties hereby stipulate the following amended pre-trial schedule - plaintiffs to submit pre-trial order to the Court by 4/8/05. All other deadlines are as further set forth in said Order. (Signed by Judge Sidney H. Stein on 2/10/05) (db,) (Entered: 02/22/2005)
02/16/2005		Set/Reset Deadlines: Pretrial Order due by 4/8/2005. (db,) (Entered: 02/22/2005)
02/22/2005	117	REPLY TO REPLY TO APOTEX'S THIRD AMENDED ANSWER. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (cd,) (Entered: 03/03/2005)
02/23/2005	114	ORDER; that Apotex's application to depose Dr. Robert W Colman is denied. (Signed by Judge Sidney H. Stein on 2/18/05) (pl,) (Entered: 03/01/2005)
02/23/2005	115	LETTER addressed to Judge Sidney H. Stein from Karen J. Bernstein dated 1/27/05 re: response to plaintiffs 1/25/05 letter requesting a stay and/or enjoiment. Document filed by Apotex Corp.(db,) (Entered: 03/02/2005)
02/23/2005	116	LETTER addressed to Judge Sidney H. Stein from Evan R. Chesler dated 1/25/05 re: request for an informal conference seeking protective order enjoining the deposition of Dr. Robert W. Colman. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership.(db,) (Entered: 03/02/2005)
03/01/2005	118	MOTION (FILED ON SERVICE DATE) for Reconsideration of the Court's 2/18/05 order denying defts' Appliation to depose Robert Colman MD. Document filed by Apotex Inc., Apotex Corp. (cd,) (Entered: 03/04/2005)

03/15/2005	119	REPLY MEMORANDUM OF LAW in Support re: [118] MOTION (FILED ON SERVICE DATE) for Reconsideration. Document filed by Apotex Inc., Apotex Corp.. (sac,) (Entered: 03/24/2005)
03/25/2005	120	ORDER denying [118] Motion for Reconsideration . (Signed by Judge Sidney H. Stein on 3/23/2005) (jsa,) (Entered: 03/28/2005)
03/25/2005	121	STIPULATION AND ORDERThe Court amends the pretrial schedule as follows:All parties exchange their portions of the Pre-trial order, e.g., exhibit lists, deposition designations, witness lists etc by 4/22/2005; All parties exchange objections by 5/6/2005; Plaintiffs submit Pre-trial order to the COurt on 5/13/2005; Trial, pursuant to Court order. (Signed by Judge Sidney H. Stein on 3/23/2005) (jsa,) (Entered: 03/28/2005)
03/25/2005		Set/Reset Deadlines: Pretrial Order due by 5/13/2005. Proposed Pretrial Order due by 4/22/2005. (jsa,) (Entered: 03/28/2005)
03/25/2005	122	MEMORANDUM AND OPINION # 91403 re: [81] MOTION for Reconsideration re; [76] Memorandum & Opinion filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. The Court grants Sanofi's motion for reconsideration of Judge Sweet's decision, and upon reconsideration, denies Apotex's motion to compel Sanofi to produce deposition witnesses and all correspondence after 11/4/88 bearing on the issue of why Sanofi cancelled original claims 6-9 in its prosecution of patent application 07/155,550. So Ordered. (Signed by Judge Sidney H. Stein on 3/23/05) (jco,) (Entered: 03/28/2005)
04/15/2005	123	ORDER denying [88] Motion for Leave to supplement its third amended answer, affirmative defenses and counterclaims.. (Signed by Judge Sidney H. Stein on 4/12/05) (dle,) (Entered: 04/19/2005)
04/27/2005	125	MOTION (FILED ON SERVICE DATE) for Reconsideration of Order dated 4/12/05 denying defendants' motion for leave to amend to assert an additional ground of inequitable conduct. Document filed by Apotex Inc., Apotex Corp. (Filed in the night deposit on 4/27/05 at 6:42 p.m.) (ae,) (Entered: 05/03/2005)
05/05/2005	126	ENDORSED LETTER addressed to Judge Sidney H. Stein from Richard J. Stark dated 4/25/05 re: Counsel writes to request that your Honor permit us to update the Court on the results of our negotiations on 5/6/05. So Ordered. (Signed by Judge Sidney H. Stein on 4/25/05) (jco,) (Entered: 05/05/2005)
05/09/2005	127	STIPULATION AND ORDER that all parties exchange objections to the pretrial order by 5/20/05; plaintiffs submit the pretrial order to the court by 5/27/05. (Signed by Judge Sidney H. Stein on 5/5/05) (dle,) (Entered: 05/10/2005)
05/09/2005		Set/Reset Deadlines: Pretrial Order due by 5/27/2005. (dle,) (Entered: 05/10/2005)
05/12/2005	128	ENDORSED LETTER addressed to Judge Sidney H. Stein from Karen J.

		Bernstein dated 4/27/05, Set Deadlines/Hearing as to [125] MOTION (FILED ON SERVICE DATE) for Reconsideration: Responses due by 5/18/2005; Replies due by 5/24/2005. (Signed by Judge Sidney H. Stein on 5/11/05) (sac,) (Entered: 05/13/2005)
05/20/2005	130	LETTER addressed to Judge Sidney H. Stein from Karen J. Bernstein dated 5/18/05 re: Opposition to Sanofi Plaintiffs' request to substitute Dr. Topol for Dr. Bhatt as its expert witness. Document filed by Apotex Inc., Apotex Corp..(ps,) (Entered: 05/25/2005)
05/20/2005	132	MEMORANDUM OF LAW in Opposition re: [125] MOTION (FILED ON SERVICE DATE) for Reconsideration. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (ae,) (Entered: 05/26/2005)
05/24/2005	131	Addendum to STIPULATION PROTECTIVE ORDER: subject to the approval of the Court, Teva shall be a party to the Stipulated Protective Order. Teva shall have the same privileges and responsibilities concerning Confidential Information as all other parties to the Stipulated Protective Order. Attorneys of record for Teva, eligible for access to Confidential Information under Paragraph 3 of the Stipulated Protective Order, shall include: Kirland & Ellis LLP. (Signed by Judge Sidney H. Stein on 5/20/05) (kw,) (Entered: 05/26/2005)
05/27/2005	133	ORDER. Plaintiffs Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership request to substitute Dr. Deepak Bhatt for Dr. Eric J. Topol is granted pending submission to this Court of Topol's affidavit setting forth the circumstances of and reasons for his withdrawal. Pending plaintiffs' submission of Dr. Eric J. Topol's affidavit setting forth the circumstances of and reasons for his withdrawal, the Court grants Sanofi's request to modify the scheduling Order dated 8/10/04. This modification is for the sole purpose of permitting defendants to respond to Bhatt's report and to depose Bhatt. Plaintiffs shall serve and file Topol's affidavit on or before 6/6/05. Since plaintiffs delivered Bhatt's expert report to defendants on 4/15/05, defendants shall respond to Bhatt's report and depose Bhatt on or before 6/27/05 (Signed by Judge Sidney H. Stein on 5/26/05) (yv,) (Entered: 05/31/2005)
06/01/2005	134	DECLARATION of Eric J. Topol. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc.. (jmi,) (Entered: 06/03/2005)
06/07/2005	135	MOTION (FILED ON SERVICE DATE) for an Order admitting Kevin A. Keeling Pro Hac Vice as co-counsel. Document filed by Apotex Inc., Apotex Corp. (yv,) (Entered: 06/09/2005)
06/07/2005	136	DECLARATION of Karen J. Bernstein in Support re: [135] MOTION (FILED ON SERVICE DATE) for Kevin A. Keeling to Appear Pro Hac Vice. Proposed Order attached. Document filed by Apotex Inc., Apotex Corp. (yv,) (Entered: 06/09/2005)
06/09/2005	137	ORDER; re: granting [135] MOTION (FILED ON SERVICE DATE) for Kevin A. Keeling to Appear Pro Hac Vice. filed by Apotex Corp.,

		Apotex Inc., (Signed by Judge Sidney H. Stein on 6/7/05) (pl,) (Entered: 06/13/2005)
06/17/2005		CASHIERS OFFICE REMARK on [137] Order in the amount of \$25.00, paid on 6/15/05, Receipt Number 546682. (mlo,) (Entered: 06/17/2005)
06/22/2005	138	STIPULATION AND ORDER plaintiff's Sanofi-Aventis, Sanofi-Synthelabo Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership and Defendants Apotex Inc. and Apotex Corp., hereby stipulate, subject to the consent of the Court, to the following amended pre-trial schedule: Submissions pursuant to Judge Stein's Individual Practice Rule 3(B). Apotex to serve its supplemental expert report(s), if any, in response Dr. Bhatt's expert report. Trial: Pursuant to Court Order. (Signed by Judge Sidney H. Stein on 6/20/05) (jco,) (Entered: 06/22/2005)
07/01/2005	139	ORDER ADMITTING ATTORNEY PRO HAC VICE. William Charles Youngblood is permitted to appear pro hac vice in association with movant as co counsel to Apotex Inc. and Apotex Corp. in this action. (Signed by Judge Sidney H. Stein on 7/1/05) (dle,) (Entered: 07/06/2005)
07/01/2005		Transmission to Attorney Admissions Clerk. Transmitted re: [139] Order Admitting Attorney Pro Hac Vice, to the Attorney Admissions Clerk for updating of Attorney Information. (dle,) (Entered: 07/06/2005)
07/13/2005	140	JOINT PRETRIAL ORDER fld. (Signed by Judge Sidney H. Stein on 7/11/05) (cd,) (Entered: 07/13/2005)
07/14/2005	141	ORDER denying [125] Motion for Reconsideration, as further set forth in this document. (Signed by Judge Sidney H. Stein on 7/11/05) (cd,) (Entered: 07/14/2005)
07/15/2005	145	NOTICE OF MOTION (FILED ON SERVICE DATE) to Preclude testimony by defts untimely identified experts. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	146	MEMORANDUM OF LAW in Support re: [145] MOTION (FILED ON SERVICE DATE) to Preclude.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	147	NOTICE MOTION (FILED ON SERVICE DATE) to Preclude Relitigation of facts found by the Federal Court of Canada. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	148	MEMORANDUM OF LAW in Support re: [147] MOTION (FILED ON SERVICE DATE) to Preclude.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)

07/15/2005	149	NOTICE OF MOTION (FILED ON SERVICE DATE) to Preclude testimony by defts' scientific experts. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	150	NOTICE OF MOTION (FILED ON SERVICE DATE) to Preclude expert testimony by Frank Bernatowicz. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	151	NOTICE OF MOTION (FILED ON SERVICE DATE) to Preclude testimony of Michael Sofocleous. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (pa,) (Entered: 07/19/2005)
07/15/2005	152	TRIAL MEMORANDUM. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership.(pa,) (Entered: 07/19/2005)
07/15/2005	153	Pltffs Proposed Jury Instructions.(pa,) (Entered: 07/19/2005)
07/15/2005	176	Proposed Voir Dire Questions. Document filed by Apotex Inc., Apotex Corp. Received in night deposit box on 7/15/05 at 8:31 p.m.(db,) (Entered: 09/09/2005)
07/15/2005	177	PRETRIAL MEMORANDUM OF LAW on Order of Proof at Trial in view of admission of infringement. Document filed by Apotex Inc., Apotex Corp. Received in night deposit box on 7/15/05 at 8:30 a.m.(db,) (Entered: 09/09/2005)
07/15/2005	178	Proposed Jury Instructions. Document filed by Apotex Inc., Apotex Corp.(db,) Modified on 9/9/2005 (db,). Received in night deposit box on 7/15/05 at 8:31 p.m. (Entered: 09/09/2005)
07/15/2005	179	PROPOSED VERDICT FORM. Document filed by Apotex Inc., Apotex Corp. (db,) Modified on 9/9/2005 (db,). Received in night deposit box on 7/15/05 at 8:31 p.m. (Entered: 09/09/2005)
09/02/2005	172	MOTION (FILED ON SERVICE DATE) to Strike Document No. [147]. Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 09/06/2005)
09/02/2005	173	MEMORANDUM OF LAW in Support re: [172] MOTION (FILED ON SERVICE DATE) to Strike Document No. [147]. Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 09/06/2005)
09/02/2005	174	DECLARATION of Mona Gupta in Support re: [172] MOTION (FILED ON SERVICE DATE) to Strike Document No. [147]. (jco,) (Entered: 09/06/2005)
09/06/2005	175	AMENDED CERTIFICATE OF SERVICE of Motion to Strike and Preclude with Supporting Documents served on counsel for plaintiffs on 9/6/05. Service was accepted by Hand Delivery. Service was made by Federal Express Mail. Document filed by Apotex Inc., Apotex Corp.

		(db,) (Entered: 09/08/2005)
09/14/2005	180	ENDORSED LETTER addressed to Judge Sidney H. Stein from Evan R. Chesler dated 7/20/05 re: determine the order of proof at trial. 10/31- parties to complete depositions of experts responding to Dr. Blatt. 11/6- Parties to serve response to remaining motions, and objections to jury instructions. 1/6/06- parties to reply to remaining motions. 4/3/06-Trial. No determination is being made at this time on the motion for consolidation, pending briefing on the motions to preclude relitigation of facts found in Canada. (Signed by Judge Sidney H. Stein on 9/12/05) (kco,) (Entered: 09/16/2005)
09/22/2005	182	MEMORANDUM OF LAW in Opposition to Apotex's Memorandum of Law in Support of [32] Motion. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (db,) (Entered: 09/28/2005)
09/22/2005	185	DECLARATION of Stephen G. Davies, D. Phil in Support re: [182] Memorandum of Law in Opposition. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (db,) (Entered: 09/28/2005)
09/26/2005	183	MEMORANDUM OF LAW in Opposition to Apotex's Pre-Trial Memorandum of law on Order of Proof at trial in View of Admission of Infringement ([30] Motion). Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (db,) (Entered: 09/28/2005)
09/26/2005	184	DECLARATION of Stephen R. Byrn in Support re: [182] Memorandum of Law in Opposition. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (db,) (Entered: 09/28/2005)
09/29/2005	186	REPLY MEMORANDUM OF LAW in Support re: [172] MOTION (FILED ON SERVICE DATE) to Strike Document No. [147].. Document filed by Apotex Inc., Apotex Corp.. (dle,) (Entered: 09/30/2005)
10/07/2005	187	MEMORANDUM OF LAW in Response to Sanofi's Opposition to Apotex's pre-Trial Memorandum on Order of Proof at Trial in View of Admission of Infringement. Document filed by Apotex Corp.. (djc,) (Entered: 10/11/2005)
10/18/2005	189	SUPPLEMENTAL REPLY MEMORANDUM OF LAW (CITING NEW AUTHORITY) IN RESPONSE TO PLAINTIFFS' MEMORANDUM OF LAW IN OPPOSITION TO APOTES'S PRE-TRIAL MEMORANDUM OF LAW IN SUPPORT OF CLAIM CONSTRUCTION OF CLAIMS 1,2,8, 11 AND 12 of U.S. Patent 4,529,596. Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 10/19/2005)
10/31/2005	190	RESPONSE to Defendants' Supplemental Reply Memorandum of Law (Citing New Authority) in Response to Plaintiffs' Memorandum of Law in Opposition to Apotex's Memorandum of Law in Support of Claim Construction of Claims 1,2,8,11 and 12 of U.S. Patent No. 4,529,596 (Apotex Motion NO. 32). Document filed by Sanofi-Synthelabo, Sanofi-

		Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 11/01/2005)
11/07/2005	191	MEMORANDUM OF LAW in Opposition re: [151] MOTION In Limine to Preclude the testimony of Michael Sofocleous. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp. (db,) (Entered: 11/08/2005)
11/07/2005	192	DECLARATION of Karen J. Bernstein in Support re: [191] Memorandum of Law in Opposition to Motion. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp. (db,) (Entered: 11/08/2005)
11/07/2005	193	DECLARATION of Karen J. Bernstein in Support re: [147] MOTION (FILED ON SERVICE DATE) to Preclude. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp. (db,) (Entered: 11/08/2005)
11/07/2005	194	EXHIBIT to [193] Declaration VOLUME I. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp.(db,) (Entered: 11/08/2005)
11/07/2005	195	EXHIBIT to [193] Declaration VOLUME II. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp.(db,) (Entered: 11/08/2005)
11/07/2005	223	MEMORANDUM OF LAW in Opposition re: [22] Motion to Compel. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dle,) (Entered: 11/08/2005)
12/22/2005	230	REPLY MEMORANDUM OF LAW in Support of Motion to Preclude Plaintiffs from Offering Evidence of copying as a Secondary Consideration of Non-Obviousness (Apotex Motio No. 15) Document filed by Apotex Inc., Apotex Corp., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.. (dj,) (Entered: 12/27/2005)
12/29/2005	234	SUPPLEMENTAL MEMORANDUM OF LAW in Opposition re: [149] MOTION (FILED ON SERVICE DATE) to Preclude. Document filed by Apotex Inc., Apotex Corp.. Received in the night deposit box on 12/29/05 at 5:03 p.m.. (sac,) (Entered: 12/30/2005)
12/29/2005	235	REPLY MEMORANDUM OF LAW to Plaintiffs' Opposition to Apotex's Motion to exclude Sanofi's Opinion Evidence of "Long Felt Need" of Clopidogrel as a solution for the Hematotoxicity problem of Ticlopidine (Motion No. 14). Document filed by Apotex Inc., Apotex Corp.. Received in the night deposit box on 12/29/05 at 5:03 p.m.. This Document Relates to: 02cv3672 (sac,) (Entered: 12/30/2005)
12/29/2005	236	EXHIBITS TO REPLY MEMORANDUM OF LAW to Plaintiffs' Opposition to Apotex's Motion to exclude Sanofi's Opinion Evidence of "Long Felt Need" of Clopidogrel as a solution for the Hematotoxicity problem of Ticlopidine (Motion No. 14). Document filed by Apotex Inc.,

		Apotex Corp.. Received in the night deposit box on 12/29/05 at 5:03 p.m.. This Document Relates to: 02cv3672. (sac,) (Entered: 12/30/2005)
01/03/2006	239	ENDORSED LETTER addressed to Judge Sidney H. Stein from Karen J. Bernstein dated 12/22/05 re: Requests a one week extension of the deadline for filing of reply briefs in support of its in limine motions from January 6, 2006 to January 13, 2006. ENDORSEMENT: So Ordered. (Signed by Judge Sidney H. Stein on 12/28/05) (js,) (Entered: 01/04/2006)
01/04/2006	241	REPLY MEMORANDUM OF LAW to plaintiffs' opposition to motion to exclude experts' opinions that examiner's rejection of claims was erroneous(Motion No. 20). Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 01/05/2006)
01/04/2006	242	REPLY MEMORANDUM OF LAW to plaintiffs' opposition to defendants' motion to exclude Sanofi's Opinions and Contentions that differences in the toxicity of the enantiomers in the acute toxicity study in the '265 Patent were "unexpected" (Apotex motion no. 17). Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 01/05/2006)
01/11/2006	249	REPLY to Response to Motion re: defts' Motion to Exclude plntfs' Opinion Evidence etc. Document filed by Apotex Corp. (cd,) (Entered: 01/18/2006)
01/13/2006	250	DECLARATION of Anthony G. Creber in Support re: [147] MOTION to Preclude. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (kco,) (Entered: 01/18/2006)
01/13/2006	251	CONSOLIDATED REPLY MEMORANDUM OF LAW in Support re: [147] MOTION (FILED ON SERVICE DATE) to Preclude Relitigation of Facts and [172] MOTION (FILED ON SERVICE DATE) to Strike Document No. [147]. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (kco,) (Entered: 01/18/2006)
01/17/2006	253	REPLY MEMORANDUM OF LAW in Opposition re: [145] Motion to Preclude.. Document filed by Apotex Corp accompanied by Exhibits. (cd,) (Entered: 01/19/2006)
01/17/2006	254	REPLY MEMORANDUM OF LAW in Support re: [149] MOTION to Preclude. Document filed by Apotex Corp; accompanied by exhibits. (cd,) (Entered: 01/19/2006)
01/17/2006	255	REPLY MEMORANDUM OF LAW in Support re: Motion to in limine to exlude plntfs' hearsay evidence etc. Document filed by Apotex Corp. (cd,) (Entered: 01/19/2006)
02/09/2006	256	Local Rule 1.4DECLARATION of Anthony LoCicero re Motion for Leave to Substitute co counsel for defts Apotex et al. Document filed by Apotex Corp. et al. (cd,) (Entered: 02/10/2006)
02/10/2006	257	STIPULATION OF SUBSTITUTION OF CO-COUNSEL; Pryor

		Cashman Sherman & Flynn LLP is substituted as co-counsel for defendants Apotex Inc. and Apotex Corp. in place and stead of Amster, Rothstein & Ebenstein, LLP. (Signed by Judge Sidney H. Stein on 2/8/06) (kco,) (Entered: 02/10/2006)
02/23/2006	258	MOTION (FILED ON SERVICE DATE) for Lynn M. Terrebonne to Appear Pro Hac Vice. Document filed by Apotex Inc., Apotex Corp.. (dj,) (Entered: 02/24/2006)
02/23/2006	259	DECLARATION of Karen J. Bernstein in Support re: [258] MOTION (FILED ON SERVICE DATE) for Lynn M. Terrebonne to Appear Pro Hac Vice. Document filed by Apotex Inc., Apotex Corp. (dj,) (Entered: 02/24/2006)
02/28/2006	260	TRIAL MEMORANDUM. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jco,) (Entered: 03/01/2006)
03/01/2006	261	ORDER: The trial date is hereby adjourned from 4/3 to 6/12/2006 at 9:30 a.m. (Signed by Judge Sidney H. Stein on 2/27/2006) (lb,) (Entered: 03/01/2006)
03/14/2006	262	ORDER granting [258] Motion for Lynn M. Terrebonne to Appear Pro Hac Vice . (Signed by Judge Sidney H. Stein on 5/13/06) (cd,) (Entered: 03/14/2006)
03/14/2006		Transmission to Attorney Admissions Clerk. Transmitted re: [262] Order on Motion to Appear Pro Hac Vice, to the Attorney Admissions Clerk for updating of Attorney Information. (cd,) (Entered: 03/14/2006)
03/14/2006	263	ADDENDUM TO STIPULATED PROTECTIVE ORDER...regarding procedures to be followed that shall govern the handling of confidential material.... (Signed by Judge Sidney H. Stein on 3/13/2006) (lb,) (Entered: 03/14/2006)
03/24/2006	264	ORDER; the trial in this matter is adjourned sine die. The matter is placed on the suspense calendar. The parties are directed to inform the Court when the appropriate regulators have approved or rejected the parties' proposed settlement, and in any event to notify the Court on or before 5/20/06 as to the status of this matter, if this action has not been dismissed by that date. (Signed by Judge Sidney H. Stein on 3/23/06) (sac,) (Entered: 03/24/2006)
03/27/2006	265	ORDER; dismissing, without prejudice [145] Motion to Preclude, dismissing [147] Motion to Preclude, dismissing [149] Motion to Preclude, dismissing [150] Motion to Preclude, dismissing [151] Motion to Preclude, dismissing [172] Motion to Strike. (Signed by Judge Sidney H. Stein on 3/24/06) (sac,) (Entered: 03/27/2006)
08/16/2006	267	MOTION for Preliminary Injunction. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	269	DECLARATION of Hugh O'Neill in Support re: [267] MOTION for

		Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	270	DECLARATION of Jerry A.Hausman in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	271	DECLARATION of Jerome Durso in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	273	DECLARATION of Stephen G.Davies in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	274	DECLARATION of Stephen R.Hanson in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	275	DECLARATION of Alain Badore in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	276	DECLARATION of Stephen R Byrn in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	277	MEMORANDUM OF LAW in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/16/2006	278	DECLARATION of Shayne Gad in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (dj,) (Entered: 08/17/2006)
08/17/2006	266	MOTION for Leave to File Amicus Brief in Opposition to Plaintiffs' Motion for Preliminary Injunction. Document filed by National Association of Chain Drug Stores. (Attachments: # 1 Amicus Brief in Opposition to Plaintiffs' Motion for Preliminary Injunction# 2 Exhibit A - E# 3 Exhibit F - G# 4 Exhibit H# 5 Exhibit I)(Davis, Zachary) (Entered: 08/17/2006)
08/17/2006	272	NOTICE of Appearance Pro Hac Vice. Document filed by National Association of Chain Drug Stores. (Attachments: # 1 Exhibit 1 - 3)

		(Davis, Zachary) (Entered: 08/17/2006)
08/18/2006	280	AMICUS CURIAE MEDCO HEALTH SOLUTIONS, INC.'S MEMORANDUM OF LAW in Opposition re: [267] MOTION for Preliminary Injunction.. (jmi,) (Entered: 08/21/2006)
08/21/2006	281	LETTER addressed to Judge Stein from Robert Silver dated 8/15/06: re plntf's preliminary injunction papers. Document filed by Apotex Inc. (cd,) (Entered: 08/21/2006)
08/21/2006	282	LETTER addressed to Judge Stein from David Greenwald dated 8/15/06 re Apotex' letter doc #281. Document filed by Sanofi-Synthelabo.(cd,) (Entered: 08/21/2006)
08/21/2006	283	LETTER addressed to Judge Stein from John Grogan dated 8/17/06: Mr. Chesler's letter seeking to quash the subpoena served on Mr. Andrew Bodnar. (cd,) (Entered: 08/21/2006)
08/21/2006	284	DECLARATION of Robert L. Baechtold in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	285	DECLARATION of Stephen G. Davies in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	286	DECLARATION of Jerry A. Hausman in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	287	DECLARATION of Stephen R. Hanson in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	288	DECLARATION of Hugh O'Neil in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	289	DECLARATION of Alain Badorc in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	290	DECLARATION of Jerome Durso in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	291	DECLARATION of Stephen R. Byrn in Support re: [267] MOTION for

		Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/21/2006	292	DECLARATION of Angie K. Young in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, National Association of Chain Drug Stores. (jmi,) (Entered: 08/22/2006)
08/21/2006	293	REPLY MEMORANDUM OF LAW in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jmi,) (Entered: 08/22/2006)
08/22/2006	294	filed Plaintiffs' Deposition Designations. Document filed by Sanofi-Synthelabo et al. (cd,) (Entered: 08/23/2006)
08/22/2006	295	REPLY MEMORANDUM OF LAW in Support re: [267] MOTION for Preliminary Injunction.. Document filed by Sanofi-Synthelabo et al. (cd,) (Entered: 08/23/2006)
08/24/2006	296	TRANSCRIPT of proceedings held on 8/17/06 before Judge Sidney H. Stein. (cd,) (Entered: 08/24/2006)
08/25/2006	297	TRANSCRIPT of proceedings held on 8/7/2006 @ 9:30 A.M. before Judge Sidney H. Stein. (lb,) (Entered: 08/25/2006)
08/25/2006	298	TRANSCRIPT of proceedings held on 8/1/2006 @ 5:10 P.M. before Judge Sidney H. Stein. (lb,) (Entered: 08/25/2006)
08/25/2006	299	TRANSCRIPT of proceedings held on 8/4/2006 @ 10:00 A.M. before Judge Sidney H. Stein. (lb,) (Entered: 08/25/2006)
08/25/2006	300	TRANSCRIPT of proceedings held on 8/11/06 before Judge Sidney H. Stein. (db,) (Entered: 08/25/2006)
08/28/2006	303	DECLARATION of Mee-Sung Shim in Support re: [267] MOTION for Preliminary Injunction. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jar,) (Entered: 08/30/2006)
08/31/2006	304	MEMORANDUM AND OPINION # 93623 re: [267] MOTION for Preliminary Injunction filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. Because the four relevant factors set forth by the Federal Circuit weigh in favor of the grant of a preliminary injunction and Apotes's equitable defenses to an injunction are without merit, Sanofi's motion is granted to the extent that Apotex shall be enjoined from infringing Sanofi's '265 patent during the pendency of this action. Sanofi shall post a bond pursuant to F.R.C.P. 65(c) in the amount of \$400 million. (Signed by Judge Sidney H. Stein on 8/31/06) (jco,) Additional attachment(s) added on 9/1/2006 (jco,). Modified on 9/1/2006 (rw,). (Entered: 09/01/2006)
08/31/2006	312	DECLARATION of Robert Silver, Esq., in Support of Memorandum of

		Law in Opposition to Plaintiffs' Motion for TRO/Preliminary Injunction. Document filed by Apotex Corp.. (dj,) (Entered: 09/07/2006)
08/31/2006	313	DECLARATION of Bernard Sherman in Support of Apotex' Memorandum of Law in Opposition to Plaintiffs' Motion for a Preliminary Injunction. Document filed by Apotex Inc., Apotex Corp.. (dj,) (Entered: 09/07/2006)
08/31/2006	314	DECLARATION of Mona Gupta, Esq. in Support of Apotex' Memorandum of Law in Opposition to Plaintiffs' Motion for Preliminary Injunction. Document filed by Apotex Inc., Apotex Corp.. (dj,) (Entered: 09/07/2006)
08/31/2006	315	Deposition Designation of the Deposition Transcript of Stephen Byrn. Document filed by Apotex Corp. (cd,) (Entered: 09/08/2006)
08/31/2006	316	Deposition Desingations of Stephen Hanson. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	317	Deposition Desingations of the Deposition Transcript of Shayne Gad. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	318	Counter-Desingation of the Deposition Transcript of Stephen Davies. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	319	Counter-Designations of the Deposition Transcript of Gilbert Banker. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	320	Errata Sheet to the Deposition of Gilbert Banker. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	321	Counter-Designation of the Deposition Trancript of Robert McClelland. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	322	Errata to the Deposition of Robert McClelland. Document filed by Apotex Corp. (cd,) (Entered: 09/08/2006)
08/31/2006	323	Counter-Designation of the Deposition Transcript of James Hendrickson. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	324	Errata Sheet to the Deposition of James Hendrickson. Document filed by Apotex Corp. (cd,) (Entered: 09/08/2006)
08/31/2006	325	Counter-Desingations of the Deposition Transcript of Robert Snyder. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	326	Errata Sheet to the Deposition of Robert Snyder. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
08/31/2006	327	Errata Sheet to the Deposition of Cecil Pace-Asciak. Document filed by Apotex Corp.. (cd,) (Entered: 09/08/2006)
09/01/2006	305	ORDER; for the reasons set forth in the Opinion dated 8/31/06, plaintiffs' motion for a preliminary injunction is hereby granted insofar as defendants Apotex, Inc. and Apotex, Corp. and their agents, servants,

		etc. are enjoined from engaging in any activity that infringes U.S. Patent No. 4,847,265 during the pendency of this action, and the motion is hereby denied to the extent it seeks a recall of defendants' generic clopidogrel bisulfate product. Plaintiffs shall post a bond pursuant to F.R.C.P. 65(c) in the amount of \$400 million by 9/5/2006. (Signed by Judge Sidney H. Stein on 8/31/06) (kco,) (Entered: 09/01/2006)
09/01/2006	306	ORDER; the Clerk of the Court is to transfer the funds from the Registry of the Court of the Southern District of New York to the Registry of the Court of the Southern District of Texas for the purpose of placing said funds in the Court Registry Investment System, Interset Bearing Account..... (Signed by Judge Sidney H. Stein on 8/31/06) (kco,) (Entered: 09/01/2006)
09/01/2006	307	TRO BOND # CGB8796851 in the amount of \$ 200,000,000.00 posted by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jf,) (Entered: 09/01/2006)
09/01/2006	308	TRO BOND # 104796013 in the amount of \$ 200,000,000.00 posted by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. NOTE: This and the previous docketed bond total \$400,000,000.00(jf,) (Entered: 09/01/2006)
09/01/2006	309	ENDORSED LETTER addressed to Sidney H. Stein from Manny D. Pokotilow dated 9/1/06 re: Apotex Requests that the Court stay the preliminary injunction pending an appeal to the Court of appeals. ENDORSEMENT: motion DENIED. So Ordered. (Signed by Judge Sidney H. Stein on 9/1/06) (js,) (Entered: 09/05/2006)
09/05/2006	310	ENDORSED LETTER addressed to Judge Sidney H. Stein from Manny D. Pokotilow dated 9/1/06 re: denying dft. Apotex requests that the Court stay the preliminary injunction pending an appeal to the Court of Appeals for the Federal Circuit. (Signed by Judge Sidney H. Stein on 9/1/06) (pl,) (Entered: 09/05/2006)
09/05/2006	311	NOTICE OF APPEAL TO THE FEDERAL CIRCUIT from [305] Order,,, 304 Memorandum & Opinion,. Document filed by Apotex Inc., Apotex Corp. Filing fee \$ 455.00, receipt number E 589379. Copies of Notice of Appeal to the Federal Circuit mailed to Attorney(s) of Record: Cravath, Swaine & Moore LLP and Fitzpatrick Cella Harper & Scinto. (nd,) (Entered: 09/05/2006)
09/05/2006		Transmission of Notice of Appeal to the District Judge re: [311] Notice of Appeal to the Federal Circuit,. (nd,) (Entered: 09/05/2006)
09/05/2006		Transmission of Notice of Appeal and Certified Copy of Docket Sheet to US Court of Appeals for the Federal Circuit re: [311] Notice of Appeal to the Federal Circuit,. (nd,). (Entered: 09/05/2006)
09/19/2006	328	ORDER re: [306] Order. The "Order For Placing Funds into C.R.I.S." dated 8/31/06 is vacated. So Ordered. (Signed by Judge Sidney H. Stein on 9/19/06) (jco,) (Entered: 09/19/2006)

09/29/2006	329	DECLARATION of Robert Silver, Esq. in Support of Apotex's Motion for Leave to File a Supplemental Pleading. Document filed by Apotex Corp.. (dj,) (Entered: 10/04/2006)
09/29/2006	330	DECLARATION of Robert Silver, Esq. in Support of Motion for Leave to File a Supplemental Pleading. Document filed by Apotex Inc., Apotex Corp.. (dj,) (Entered: 10/11/2006)
10/13/2006	331	MEMORANDUM OF LAW in Opposition to Apotex's Motion for Leave to File a Supplemental Pleading. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (Filed in the night deposit on 10/13/06 at 5:07 p.m.) (ae,) (Entered: 10/19/2006)
10/23/2006	332	REPLY MEMORANDUM OF LAW in Support to Apotex's Motion for Leave to File a Supplemental Pleading. Document filed by Apotex Inc., Apotex Corp., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.. (pl,) (Entered: 10/24/2006)
10/23/2006	333	DECLARATION of Karen J. Bernstein in Support of Pryor Cahsman Sherman & Flynn LLP's notice of Withdrawal as Counsel. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp.. (dj,) (Entered: 10/25/2006)
10/24/2006	334	ORDER that Pryor Cashman Sherman & Flynn LLP is hereby withdrawing as local counsel to dfts Apotex, Inc. and Apotex Corp. (Signed by Judge Sidney H. Stein on 10/23/06) (dle,) (Entered: 10/25/2006)
11/01/2006	335	TRANSCRIPT of proceedings held on 08/18,21/06 before Judge Sidney H. Stein. (es,) (Entered: 11/01/2006)
11/02/2006	336	OPINION AND ORDER # 93890: Defendants Apotex Inc. and Apotex Corp. (collectively, "Apotex") move pursuant to Fed. R. Civ. P. 15(a) and 15(d) to amend and supplement their Third Amended Answer, resulting in a Fourth Amended Answer, in this action. The motion is denied to the extent Apotex seeks to add the defense of unclean hands and the counterclaim for breach of contract on the grounds that adding those claims would unduly prejudice plaintiffs. The motion is granted, however, insofar as it seeks to amend and supplement the answer with additional antitrust counterclaims. In addition, those antitrust counterclaims are severed pursuant to Fed. R. Civ. P. 21 and stayed pending resolution of the issues scheduled for trial commencing January 22, 2007. Apotex is directed to file a Fourth Amended Answer pursuant to this Opinion and Order within 20 days. (Signed by Judge Sidney H. Stein on 11/2/06) (pl,) Modified on 11/3/2006 (rw,). (Entered: 11/02/2006)
11/07/2006	337	MOTION for Lynn M. Terrebonne to Withdraw as Attorney. Document filed by Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp., Apotex Inc., Apotex Corp. Proposed Order attached. (db,) (Entered: 11/09/2006)
11/14/2006	338	ORDER; Lynn M. terrebonne is allowed to withdraw as counsel of

		record. All other counsel remain as counsel of record for Apotex, Inc. and Apotex Corp. (Signed by Judge Sidney H. Stein on 11/13/06) (kco,) (Entered: 11/16/2006)
11/17/2006	340	FOURTHE AMENDED ANSWER to Complaint for Patent Infringement, Affirmative Defenses, and Amended Counterclaims. Document filed by Apotex Inc., Apotex Corp..(dj,) (Entered: 11/28/2006)
11/27/2006	339	REPLY To the Coutneclaims in Apotex's Fourth Amended Answer. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc. (cd,) (Entered: 11/28/2006)
11/28/2006	341	LETTER addressed to Judge Stein from Ena Brooks, non party dated 11/21/06 re expensive drugs. (cd,) (Entered: 12/06/2006)
12/20/2006	342	MOTION for James J. Kozuch to Appear Pro Hac Vice. Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 12/21/2006)
12/28/2006	343	MOTION for Robert B. Breisblatt to Appear Pro Hac Vice. Document filed by Apotex Inc., Apotex Corp. (jco,) (Entered: 01/03/2007)
01/03/2007	344	ORDER granting 343 Motion for Robert B. Breisblatt to Appear Pro Hac Vice in association with movant as co counsel to Apotex, Inc. and Apotex Corp. (Signed by Judge Sidney H. Stein on 12/28/06) (dle,) (Entered: 01/04/2007)
01/03/2007		Transmission to Attorney Admissions Clerk. Transmitted re: [344] Order on Motion to Appear Pro Hac Vice, to the Attorney Admissions Clerk for updating of Attorney Information. (dle,) (Entered: 01/04/2007)
01/03/2007	346	ORDER; a pretrial conf having been held on December 28, 2006 with attorneys for both parties present, it is hereby ordered that, forth reasons set forth on the record today, the following motions are granted/denied/withdrawn as set forth in this Order...; (Signed by Judge Sidney H. Stein on 12/28/06); Motions previously terminated; (dj,) (Entered: 01/05/2007)
01/03/2007	347	MOTION to increase the Injunction Bond. Document filed by Apotex Inc., Apotex Corp.. (dj,) (Entered: 01/05/2007)
01/03/2007	349	LETTER addressed to Judge Sidney H. Stein from David Greenwald dated 12/22/06 re: plaintiffs withdraw their motion to preclude relitigation of facts found by the federal court of Canada. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership.(dle,) (Entered: 01/11/2007)
01/08/2007		CASHIERS OFFICE REMARK on 342 Motion to Appear Pro Hac Vice in the amount of \$25.00, paid on 12/20/2006, Receipt Number 600706. (jd,) (Entered: 01/08/2007)
01/08/2007		CASHIERS OFFICE REMARK on [344] Order on Motion to Appear Pro Hac Vice in the amount of \$25.00, paid on 12/28/2006, Receipt Number 601238. (jd,) (Entered: 01/08/2007)

01/08/2007	348	MEMO ENDORSEMENT granting 342 Motion for James J. Kozuch to Appear Pro Hac Vice . (Signed by Judge Barbara S. Jones on 1/5/07 (PART I)) (kco,) (Entered: 01/10/2007)
01/17/2007	350	ENDORSED LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 1/12/07 re: a response to the letter of 1/10/07 seeking an extension of time. ENDORSEMENT: Pltf's request for an extension of time in which to respond to deft's motion to increase the bond is granted. Pltf's to respond by 2/14/07, deft's reply by 2/23/07. Pltf's request for partial relief from the protective order is denied. SO ORDERED. (Signed by Judge Sidney H. Stein on 1/16/07) (kco) (Entered: 01/18/2007)
01/17/2007		Set Deadlines: Responses due by 2/14/2007.Replies due by 2/23/2007. (kco) (Entered: 01/18/2007)
01/19/2007	351	ENDORSED LETTER addressed to Judge Sidney H. Stein from Davied Greenwald dated 1/9/07 re: granting the parties joint request for permission to use certain audio/visual equipment during the trial commencing January 22. (Signed by Judge Sidney H. Stein on 1/17/07) (pl) (Entered: 01/22/2007)
01/19/2007	352	ORDER; concerning use of cellular telephones and electronic messging devices during trial. That the individuals listed in this order, are permitted to use cellular telephones and electronic messaging devices on the 23rd Fl., including Courtroom 23A from 1/22/ until 2/26. (Signed by Judge Sidney H. Stein on 1/17/07) (pl) (Entered: 01/22/2007)
01/22/2007	353	ORDER; that the issue of damages, if necessary, will be tried separately from, and subsequent to, the current trial on liability. The schedule for the trial on damages, if needed, will be determined subsequent to the conclusion of the trial on liability. (Signed by Judge Sidney H. Stein on 1/22/07) (ae) (Entered: 01/23/2007)
01/22/2007	354	ORDER CONCERNING TEMPORARY INSTALLATION OF INTEREST CONNECTION IN COURTROOM; Plaintiffs, Sanofi-Aventis, Sanofi-Synthelabo and Birstol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership and Apotex Inc. and Apotex Corp. are permitted to install on 1/22/07, a temporary internet connection in Courtroom 23A and printers in the Courthouse for use during trial in this matter. (Signed by Judge Sidney H. Stein on 1/22/07) (ae) (Entered: 01/23/2007)
01/22/2007		MEMORANDUM TO THE DOCKET CLERK: Trial begun and continued 1/22, 1/23, 1/24, 1/25, 1/29-1/31, 2/1, 2/5-2/8, 2/13-2/15. Trial concluded. Total trial days 15. (jco) (Entered: 03/05/2007)
02/01/2007	355	MANDATE of USCA for the Federal Circuit(Certified Copy) as to [311] Notice of Appeal to the Federal Circuit, filed by Apotex Inc., Apotex Corp. USCA for the Federal Circuit Case Number 06-1613. Ordered, Adjudged and Decreed that the judgment of the District Court is AFFIRMED. Jan Horbaly, Clerk USCA for the Federal Circuit. Issued As Mandate: 1/26/2007. (nd) (Entered: 02/01/2007)

02/28/2007	359	STIPULATION AND ORDER concerning financial evidence from preliminary injunction hearing. (Signed by Judge Sidney H. Stein on 2/28/2007) (jmi) (Entered: 03/02/2007)
03/02/2007	360	DEFENDANTS' POST-TRIAL PROPOSED FINDINGS OF FACT AND CONCLUSIONS OF LAW. Document filed by Apotex Inc., Apotex Corp.(rw) (Entered: 03/06/2007)
03/06/2007	362	STIPULATION AND ORDER CONCERNING PRELIMINARY INJUNCTION HEARING EVIDENCE: It is hereby agreed that the Witnesses testimony shall be deemed part of the trial record as if that testimony had been offered at trial and the following exhibits used at the hearing, shall be deemed part of the trial record as if those exhibits had been offered and admitted at trial. (Signed by Judge Sidney H. Stein on 2/15/07) (js) (Entered: 03/07/2007)
03/07/2007	361	TRANSCRIPT of proceedings held on 12/28/06 before Judge Sidney H. Stein. (jbe) (Entered: 03/07/2007)
03/16/2007	363	Plaitiffs' Proposed Finding of Fact and Conclusion of Law. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (jar) (Entered: 03/20/2007)
03/29/2007	366	REPLY in support re: [360] Proposed Findings of Fact Document filed by Apotex Inc., Apotex Corp.. (tro) (Entered: 04/03/2007)
04/02/2007	364	TRANSCRIPT of proceedings held on 2/15/2007 before Judge Sidney H. Stein. (jmi) (Entered: 04/02/2007)
04/03/2007	365	TRANSCRIPT of proceedings held on 2/6,7,8,9,13,14/2007 before Judge Sidney H. Stein. (jmi) (Entered: 04/03/2007)
04/26/2007	367	TRANSCRIPT of proceedings held on 1/22,23,24,25,29/2007 before Judge Sidney H. Stein. (jar) (Entered: 04/26/2007)
04/26/2007	368	TRANSCRIPT of proceedings held on 1/30,31/2007; 2/1,5/2007 before Judge Sidney H. Stein. (jar) (Entered: 04/26/2007)
06/19/2007	369	OPINION AND ORDER Apotex has concededly infringed Sanofi's '265 patent. This Court now finds that Apotex has failed to prove by clear and convincing evidence that the '365 patent is invalid or unenforceable and Sanofi is entitled to a permanent injunction prohibiting Apotex from further infringement. 35 U.S.C. 271(e)(4)(B). Damages will be set in an amount to be determined through future proceedings. 35 U.S.C 271(e)(4)(C). Accordingly, judgment will be entered in favor of Sanofi. Apotex, Inc. and Apotex Corp. and their agents, servants, employees, and other representatives, and all persons acting in concert with them, are hereby permanently enjoined from engaging in any activity that infringes U.S. Patent No. 4,847,265. So Ordered. (Signed by Judge Sidney H. Stein on 6/19/07) (jco) (Entered: 06/19/2007)
06/19/2007		Transmission to Judgments and Orders Clerk. Transmitted re: 369 Memorandum & Opinion, to the Judgments and Orders Clerk. (jco)

		(Entered: 06/19/2007)
06/19/2007	370	CLERK'S JUDGMENT in favor of Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelabo Inc. against Apotex Corp., Apotex Inc. that damages will be awarded at a later proceeding and defts are permanently enjoined from engaging in any activity that infringes on US Patent No. 4,847,265. (Signed by J. Michael McMahon, Clerk on 6/19/07) (jf) (Entered: 06/19/2007)
06/19/2007	371	ORDER, dismissing [347] Motion for increase bond. The motion is dismissed in light of the Opinion & Order dated today finding that Apotex has not proved by clear and convincing evidence that U.S. Patent No. 4,847,265 is invalid or unenforceable and entering a permanent injunction against further infringement of that patent by Apotex. (Signed by Judge Sidney H. Stein on 6/19/07) (pl) Modified on 6/21/2007 (KA). (Entered: 06/20/2007)
06/19/2007	374	LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 12/22/07 re: Apotex withdrawing Motion's [10],[12],[13] and [25]. Document filed by Apotex Inc., Apotex Corp.(db) (Entered: 06/26/2007)
06/21/2007	372	ORDER; that upon plaintiffs' application for an order releasing the Bonds and defendants' consent thereto; that the Bonds are released and the surety companies named in the Bonds, Zurich American Insurance Company, Fidelity and Deposit Company of Maryland, and Travelers Casualty and Surety Company of America, are fully and unconditionally discharged, released and exonerated from any and all past, present and future liability arising under or in connection w/ the issuance of the Bonds. (Signed by Judge Sidney H. Stein on 6/21/07) (ae) Modified on 6/21/2007 (Espinell, Antonia). (Entered: 06/21/2007)
06/22/2007	373	NOTICE OF APPEAL TO THE FEDERAL CIRCUIT from 369 Memorandum & Opinion [370] Clerk's Judgment,. Document filed by Apotex Inc., Apotex Corp. Filing fee \$ 455.00, receipt number E 619107. Copies of Notice of Appeal mailed to attorney(s) for record: Fitzpatrick, Cella, Harper & Scinto and Cravath, Swaine & Moore. (nd) (Entered: 06/22/2007)
06/22/2007		Transmission of Notice of Appeal to the District Judge re: [373] Notice of Appeal to the Federal Circuit,. (nd) (Entered: 06/22/2007)
06/22/2007		Transmission of Notice of Appeal and Certified Copy of Docket Sheet to US Court of Appeals for the Federal Circuit re: [373] Notice of Appeal to the Federal Circuit,. (nd) (Entered: 06/22/2007)
06/25/2007	375	ENDORSED LETTER addressed to Judge Sidney H. Stein from David Greenwald dated 6/12/2007 re: Apotex request a further opportunity to respond to the substance of the positions Apotex has taken. In the meanwhile, we will continue to attempt to resolve with Apotex the outstanding issues. ENDORSEMENT: The parties should continue to try to resolve this. If they cannot, plaintiffs may respond to defendants' 6/8/2007 letter by July 3. Responses due by 7/3/2007. SO ORDERED.

		(Signed by Judge Sidney H. Stein on 6/22/2007) (jmi) (Entered: 06/28/2007)
06/26/2007	377	MOTION to Amend/Correct [370] Clerk's Judgment,. Document filed by Sanofi-Synthelabo, Sanofi-Synthelabo Inc., Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership.(pl) (Entered: 07/09/2007)
06/29/2007	376	AMENDED JUDGMENT, in favor of Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelabo Inc. against Apotex Corp., Apotex Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. that plttfs. are entitled to a permanent injunction and damages will be set at a later proceeding. (Signed by Judge Sidney H. Stein on 6/28/07) (jf) (Entered: 06/29/2007)
07/10/2007		USCA Case Number 2007-1438 from the US Courts of Appeal for the Federal Circuit assigned to [373] Notice of Appeal to the Federal Circuit, filed by Apotex Inc., Apotex Corp.. (nd) (Entered: 07/10/2007)
07/10/2007		Mailed notice of Right to Appeal re: [376] Amended Judgment to Attorney(s) of Record: Robert Louis Baechtold, Thomas H. Beck, Robert B. Breisblatt, William J. Castillo, Bruce J. Chasan, Evan R Chesler, Zachary R. Davis, Allan H. Fried, David Noah Greenwald, Mona Gupta, Kevin A. Keeling, James Kozuch, John D. Murnane, Manny D. Pokotilow, Robert S. Silver, William Ericson Solander, Richard J Stark, William C. Youngblood. (tve) (Entered: 09/11/2007)
07/11/2007	378	STIPULATION AND ORDER CONCERNING EXHIBITS USED AT TRIAL: WHEREAS during the trial in the above-captioned action, the parties used certain exhibits in connection with the presentation of their respective cases to the Court; WHEREAS the Court has requested that the parties propose and agree upon a list of exhibits used during the trial; IT IS HEREBY AGREED that the exhibits set forth in Exhibits A and B, represent the exhibits used during the trial of the above-captioned action. SO ORDERED. (Signed by Judge Sidney H. Stein on 7/11/07) (tro) (Entered: 07/12/2007)
07/16/2007	379	STIPULATION AND ORDER that handwriting on specific documents is that of Jacqueline Laforest or Daniel Frehel (Signed by Judge Sidney H. Stein on 7/16/2007) (jmi) (Entered: 07/17/2007)
07/16/2007	380	STIPULATION AND ORDER regarding timeline of discovery of PCR 3459 (Signed by Judge Sidney H. Stein on 7/16/2007) (jmi) (Entered: 07/17/2007)
07/16/2007	381	STIPULATION AND ORDER CONCERNING CORRECTION OF TRIAL TRANSCRIPT, it is hereby agreed that the corrections set forth in Exhibits A, attached hereto, be made to the Trial Transcript. (Signed by Judge Sidney H. Stein on 3/16/2007) (jmi) Modified on 7/20/2007 (Miles, Janeen). (Entered: 07/18/2007)
07/25/2007	382	AMENDED NOTICE OF APPEAL to the Federal Circuit re: [373] Notice of Appeal to the Federal Circuit, 369 Memorandum & Opinion, [376] Amended Judgment, [370] Clerk's Judgment. Document filed by

		Apotex Inc., Apotex Corp. Copies sent to attorney(s) of record: Fitzpatrick, Cella, Harper & Scinto; Cravath, Swain & Moore. (tp) Modified on 7/25/2007 (tp). (Entered: 07/25/2007)
07/25/2007		Transmission of Notice of Appeal and Certified Copy of Docket Sheet to US Court of Appeals for the Federal Circuit re: [382] Amended Notice of Appeal. (tp) (Entered: 07/25/2007)
07/25/2007		Transmission of Notice of Appeal to the District Judge re: [382] Amended Notice of Appeal. (tp) (Entered: 07/25/2007)
08/07/2007	387	LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 3/2/07 re: Enclosed are Apotex designatons and Plaintiffs' counter-designations to the following deposition transcripts as part of the trial record. Document filed by Apotex Corp.(pl) (Entered: 08/10/2007)
08/08/2007	383	LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 7/30/07 re: Apotex respectfully requests that the Court stay paragraph 6 of the Amended Judgment pending the outcome of the appeal. (tro) (Entered: 08/09/2007)
08/08/2007	384	LETTER addressed to Judge Sidney H. Stein from David Greenwald dated 6/25/07 re: Plaintiff's move purs. to FRCP 59(e) to amend the judgment merely to clarify that plaintiffs are entitled to certain relief under specified provisions of the Federal Food, Drug and Cosmetic Act. (tro) (Entered: 08/09/2007)
08/08/2007	385	LETTER addressed to Judge Sidney H. Stein from Robert L. Baechtold dated 7/24/07 re: Letter in response to Apotex's July 20, 2007 letter motion seeking stay paragraph 6 of the Amended Judgment dated June 28, 2007. (tro) (Entered: 08/09/2007)
08/08/2007	386	ENDORSED LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 7/20/07 re: a request that the Court stay the effect of paragraph 6 of the amended judgment pending the outcome of the appeal. ENDORSEMENT: The Court has reviewed Apotex's letters dated 7/20 and 7/30 and Sanofis 7/24 letter, Apotex specifically did not oppose the proposed amendment when it was proposed. See Sanofi letter dated 6/25/07 and Exhibit A to the 7/24 letter. It has presented no valid reason to stay the effect of the language it did not oppose. In making this determination, the Court has construed the 7/20 letter as a Rule 62 (c) motion for a stay and has construed all of the eBay factors. Motion denied. SO ORDERED. (Signed by Judge Sidney H. Stein on 8/8/07) (kco) (Entered: 08/09/2007)
10/12/2007	388	ENDORSED LETTER addressed to Judge Sidney H. Stein from David Greenwald dated 10/9/07 re: plaintiff respectfully submits that it be permitted to file its opposition to Apotex's motion on the same day that it files its brief in the court of Appeals, and that its appellate brief serve as its opposition here. ENDORSEMENT: opposition to Apotex motion may be in the form of Sanofi's Fed. Circuit Brief. If that brief is not due on Oct. 17, Sanofi may submit simply its discussion - of Aventis v. Lupin, Forest Labs and Pfizer v. Apotex from its draft brief. (Signed by Judge

		Sidney H. Stein on 10/10/07) (pl) (Entered: 10/17/2007)
10/23/2007	389	ENDORSED LETTER addressed to Judge Sidney H. Stein from Robert S. Silver dated 10/5/2007 re: Pursuant to Rule 62(c), Fed.R.Civ.P., Apotex submits this letter motion and respectfully requests that the Court stay the effect of paragraph 5 of the Amended Judgment dated June 28, 2007 and signed by Judge Richard M. Berman, pending the outcome of the above appeal. ENDORSEMENT: Motion pursuant to Rule 62(c) to stay paragraph 5 of the 6/28/07 Amended Judgment is denied. The Court has considered all claiming factors. Forest Labs strongly supports the injunction and Aventis and Pfizer are distinguishable. (Signed by Judge Sidney H. Stein on 10/22/2007) (jmi) (Entered: 10/23/2007)

PACER Service Center			
Transaction Receipt			
11/09/2007 08:50:55			
PACER Login:	dp0001	Client Code:	22183-1029
Description:	Docket Report	Search Criteria:	1:02-cv-02255-SHS
Billable Pages:	24	Cost:	1.92

EXHIBIT X

APPEAL, CLOSED, RELATED

U.S. District Court
United States District Court for the Southern District of New York (Foley Square)
CIVIL DOCKET FOR CASE #: 1:04-cv-07548-SHS

Sanofi-Aventis et al v. Teva Pharmaceuticals USA, Inc. et al	Date Filed: 09/23/2004
Assigned to: Judge Sidney H. Stein	Date Terminated: 07/16/2007
Case in other court: US Court of Appeals for the Federal Circuit, 07-01521	Jury Demand: Defendant
	Nature of Suit: 830 Patent
Cause: 35:145 Patent Infringement	Jurisdiction: Federal Question

Plaintiff**Sanofi-Aventis**

represented by **Robert Louis Baechtold**
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112
(212) 218-2213
Fax: (212) 218-2200
Email: rbaechtold@fchs.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Thomas H. Beck
Sidley Austin LLP(NY)
787 Seventh Avenue
New York, NY 10019
212-839-5940
Fax: 212-839-5599
Email: tbeck@sidley.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

William Ericson Solander
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112-3801
(212) 218-2100
Fax: (212) 218-2200
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Plaintiff**Sanofi-Synthelabo, Inc.**

represented by **Robert Louis Baechtold**
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Thomas H. Beck
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

William Ericson Solander
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Plaintiff

**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

represented by **Robert Louis Baechtold**
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Thomas H. Beck
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

William Ericson Solander
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

V.

Defendant

Teva Pharmaceuticals USA, Inc.

represented by **Daniel F. Attridge**
Kirkland and Ellis LLP
153 East 53rd Street
New York, NY 10022
202 879-5012
Fax: 202 654-9555
Email: dattridge@kirkland.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Edward C. Donovan
Kirkland & Ellis
655 15th Street, N.W.
Washington, DC 20005
(202) 879-5000
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Gregory F. Corbett
Kirkland & Ellis LLP (Washington)
655 Fifteenth Street NW, Suite 1200

Washington, DC 20005
 202-879-5296
 Fax: 202-879-5200
 Email: gcorbett@kirkland.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Defendant

**Teva Pharmaceuticals Industries,
 Ltd.**

Counter Claimant

Teva Pharmaceuticals USA, Inc.

represented by **Joseph C. Gioconda**
 Kirkland & Ellis
 153 East 53rd Street
 New York, NY 10022-4675
 (212) 446-4800
LEAD ATTORNEY

V.

Counter Defendant

**Bristol-Myers Squibb Sanofi
 Pharmaceuticals Holding Partnership**

Counter Defendant

Sanofi-Aventis

Counter Defendant

Sanofi-Synthelabo, Inc.

Date Filed	#	Docket Text
09/23/2004	1	COMPLAINT against Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc.. (Filing Fee \$ 150.00, Receipt Number 520446) Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc. (db,) (Entered: 09/24/2004)
09/23/2004		CASE REFERRED TO Judge Sidney H. Stein as possibly related to 1:02-cv-2255 and 1:02-cv-3672. (db,) (Entered: 09/24/2004)
09/23/2004	2	STATEMENT OF RELATEDNESS re: that this action be filed as related to 02-cv-2255 (SHS) and 02-cv-3672 (SHS). Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc..(db,) (Entered: 09/24/2004)
09/23/2004	3	RULE 7.1 DISCLOSURE STATEMENT. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership. (db,)

		Modified on 9/24/2004 (db,). (Entered: 09/24/2004)
09/23/2004	4	RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Synthelabo, Inc. (db,) (Entered: 09/24/2004)
09/23/2004	5	RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Aventis.(db,) (Entered: 09/24/2004)
09/23/2004		SUMMONS ISSUED as to Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc. (db,) (Entered: 09/24/2004)
09/24/2004		Mailed notice to Commissioner of Patents and Trademarks to report the filing of this action. (db,) (Entered: 09/24/2004)
11/04/2004	6	RULE 7.1 DISCLOSURE STATEMENT. Document filed by Teva Pharmaceuticals USA, Inc. (jco,) (Entered: 11/08/2004)
11/04/2004	7	ANSWER to Complaint with JURY DEMAND. COUNTERCLAIM against Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc. Document filed by Teva Pharmaceuticals USA, Inc..(jco,) (Entered: 11/08/2004)
11/16/2004	8	NOTICE OF CASE ASSIGNMENT to Judge Sidney H. Stein. Judge Unassigned no longer assigned to the case. (laq,) (Entered: 11/22/2004)
11/16/2004		Magistrate Judge Ronald Ellis is so designated. (laq,) (Entered: 11/22/2004)
11/16/2004		RELATED CASES: Create association to 2:02-cv-02255-SHS.. (mj) (Entered: 04/16/2007)
11/17/2004	9	MEMORANDUM OF LAW in Opposition to Plaintiff's Motion for Consolidation. Document filed by Teva Pharmaceuticals USA, Inc.. (tr,) (Entered: 11/22/2004)
11/17/2004	10	DECLARATION of Joseph C. Gioconda in Support of Deft's opposition to Plaintiffs' Motion for Consolidation. Document filed by Teva Pharmaceuticals USA, Inc.. (tr,) (Entered: 11/22/2004)
11/18/2004	11	ORDER ADMITTING ATTORNEY PRO HAC VICE. Attorney Daniel F. Attridge for Teva Pharmaceuticals USA, Inc., Edward C. Donovan for Teva Pharmaceuticals USA, Inc., Gregory F. Corbett for Teva Pharmaceuticals USA, Inc., John C. O'Quinn for Teva Pharmaceuticals USA, Inc. granted admission Pro Hac Vice. (Signed by Judge Sidney H. Stein on 11/17/04) (yv,) Modified on 12/17/2004 (ae,). (Entered: 11/22/2004)
11/19/2004	13	MEMORANDUM OF LAW in Support of motion for consolidation. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc. (db,) (Entered: 11/29/2004)
11/19/2004	14	REPLY MEMORANDUM OF LAW in Further Support of plaintiffs motion for consolidation. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-

		Synthelabo, Inc. (db,) (Entered: 11/29/2004)
11/22/2004		Mailed notice to the attorney(s) of record. (laq,) (Entered: 11/22/2004)
11/23/2004	12	REPLY re: [7] Answer to Complaint, Counterclaim. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc. (jco,) (Entered: 11/29/2004)
11/29/2004		CASHIERS OFFICE REMARK on [11] Order Admitting Attorney Pro Hac Vice, in the amount of \$100.00, paid on 11/29/04, Receipt Number 527416. (gm,) (Entered: 11/29/2004)
01/05/2005	15	STIPULATION AND ORDER OF DISMISSAL againsty Teva Pharmaceuticals Ltd. without prejudice and without costs.... (Signed by Judge Sidney H. Stein on 12/28/04) (jf,) (Entered: 01/10/2005)
04/18/2005	17	MEMO ENDORSEMENT on plaintiffs' notice of motion for consolidation dated 10/21/2004. Plaintiffs' motion for consolidation is deemed as moot in light of the Stipulation of Stay pending judgment in the related cases. (Signed by Judge Sidney H. Stein on 4/15/2005) (jsa,) (Entered: 04/21/2005)
03/14/2006		ADDENDUM TO STIPULATED PROTECTIVE ORDER...regarding procedures to be followed that shall govern the handling of confidential material....(original filed in 02-cv-2255 as document # 263) (Signed by Judge Sidney H. Stein on 3/13/2006) (lb,) (Entered: 03/14/2006)
07/16/2007	18	JUDGMENT in favor of Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Aventis, Sanofi-Synthelabo, Inc. against Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc. and enjoining Teva Pharmaceuticals USA, Inc. from engaging in the commercial manufacture, use, offer to sell or sale within the United states, or importation into the United states of drug products as claimed in U.S. Patent No. 4,847,265, until the expiration. (Signed by Judge Sidney H. Stein on 7/12/07) (ml) (Entered: 07/16/2007)
08/13/2007	19	NOTICE OF APPEAL TO THE FEDERAL CIRCUIT from [18] Judgment. Document filed by Teva Pharmaceuticals USA, Inc. Filing fee \$ 455.00, receipt number E 623821. Copies sent to attorney(s) of record: Fitzpatrick, Cella, Harper & Scinto; Cravath, Swaine & Moore; Amster, Rothstein & Ebenstein; Budd Larner, P.C.; Caesar, Rivise, Bernstein, Cohen & Pkoktilow, Ltd. (tp) (Entered: 08/14/2007)
08/14/2007		Transmission of Notice of Appeal and Certified Copy of Docket Sheet to US Court of Appeals re: [19] Notice of Appeal to the Federal Circuit,. (tp) (Entered: 08/14/2007)
08/14/2007		Transmission of Notice of Appeal to the District Judge re: [19] Notice of Appeal to the Federal Circuit,. (tp) (Entered: 08/14/2007)
09/06/2007		USCA Case Number 2007-1521 from the US Court of Appeals for the Federal Circuit assigned to [19] Notice of Appeal to the Federal Circuit, filed by Teva Pharmaceuticals USA, Inc.. (nd) (Entered: 09/06/2007)

PACER Service Center			
Transaction Receipt			
11/09/2007 08:53:00			
PACER Login:	dp0001	Client Code:	22183-1029
Description:	Docket Report	Search Criteria:	1:04-cv-07548-SHS
Billable Pages:	3	Cost:	0.24

EXHIBIT Y

RELATED

U.S. District Court
United States District Court for the Southern District of New York (Foley Square)
CIVIL DOCKET FOR CASE #: 1:02-cv-03672-SHS

Sanofi-Synthelabo, et al v. Dr. Reddy's Labs, et al
Assigned to: Judge Sidney H. Stein
Demand: \$0
Related Case: 1:02-cv-2255
Cause: 35:271 Patent Infringement

Date Filed: 05/14/2002
Jury Demand: Both
Nature of Suit: 830 Patent
Jurisdiction: Federal Question

Plaintiff**Sanofi-Synthelabo**

represented by **Robert L. Baechtold**
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112
(212) 218-2100
LEAD ATTORNEY

Thomas H. Beck
Sidley Austin LLP(NY)
787 Seventh Avenue
New York, NY 10019
212-839-5940
Fax: 212-839-5599
Email: tbeck@sidley.com
LEAD ATTORNEY

William Ericson Solander
Fitzpatrick, Cella, Harper & Scinto
30 Rockefeller Plaza
New York, NY 10112-3801
(212) 218-2100
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Plaintiff**Sanofi-Synthelabo, Inc.**

represented by **Robert L. Baechtold**
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

William Ericson Solander
(See above for address)

LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Plaintiff

**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

represented by **Robert L. Baechtold**
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

William Ericson Solander
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

V.

Defendant

Dr. Reddy's Laboratories, Ltd.

represented by **Andrew Jay Miller**
Budin, Reisman, Kupferberg &
Bernstein, LLP
112 Madison Avenue
New York, NY 10016
973-315-4412
Fax: 9733797734
Email: amiller@budd-larner.com
LEAD ATTORNEY

Stuart David Sender
Budd, Larner, P.C. (NJ)
150 John F. Kennedy Parkway,
CN1000
Short Hills, NJ 07078-0999
(973)-379-4800 x315-4462
Fax: (973)-556-1897
Email: ssender@budd-larner.com
LEAD ATTORNEY

Defendant

Dr. Reddy's Laboratories, Inc.

represented by **Andrew Jay Miller**
(See above for address)
LEAD ATTORNEY

Stuart David Sender
(See above for address)
LEAD ATTORNEY

Movant

Apotex Corp.

represented by **Anthony F Lo Cicero**
Amster, Rothstein & Ebenstein LLC
90 Park Avenue
New York, NY 10016
212-336-8810
Fax: 212-336-8001
Email: alocicero@arelaw.com
LEAD ATTORNEY

Karen Jill Bernstein
Amster, Rothstein & Ebenstein LLC
90 Park Avenue
New York, NY 10016
212-336-8123
Fax: 212 336-8001
Email: kjbernstein@arelaw.com
LEAD ATTORNEY

Kevin A. Keeling
Caesar, Rivise, Bernstein, Cohen &
Pokotilow, Ltd.
1635 Market Street, 11th Floor
Philadelphia, PA 19103
(215)-567-2010
Fax: (215)-751-1142
Email: kkeeling@crbcp.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Movant**Apotex, Inc.**

represented by **Anthony F Lo Cicero**
(See above for address)
LEAD ATTORNEY

Karen Jill Bernstein
(See above for address)
LEAD ATTORNEY

Kevin A. Keeling
(See above for address)
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Counter Claimant**Dr. Reddy's Laboratories, Ltd.**

represented by **Andrew Jay Miller**
(See above for address)
LEAD ATTORNEY

Counter Claimant**Dr. Reddy's Laboratories, Inc.**

represented by **Andrew Jay Miller**

(See above for address)
LEAD ATTORNEY

V.

Counter Defendant

Sanofi-Synthelabo

represented by **Robert L. Baechtold**
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

Counter Defendant

Sanofi-Synthelabo, Inc.

represented by **Robert L. Baechtold**
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

Counter Defendant

**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

represented by **Robert L. Baechtold**
(See above for address)
LEAD ATTORNEY

Thomas H. Beck
(See above for address)
LEAD ATTORNEY

Counter Claimant

Dr. Reddy's Laboratories, Ltd.

represented by **Andrew Jay Miller**
(See above for address)
LEAD ATTORNEY

Stuart David Sender
(See above for address)
LEAD ATTORNEY

Counter Claimant

Dr. Reddy's Laboratories, Inc.

represented by **Andrew Jay Miller**
(See above for address)
LEAD ATTORNEY

Stuart David Sender
(See above for address)
LEAD ATTORNEY

V.

Counter Defendant**Sanofi-Synthelabo**

represented by **Robert L. Baechtold**
 (See above for address)
LEAD ATTORNEY

Thomas H. Beck
 (See above for address)
LEAD ATTORNEY

Counter Defendant**Sanofi-Synthelabo, Inc.**

represented by **Robert L. Baechtold**
 (See above for address)
LEAD ATTORNEY

Thomas H. Beck
 (See above for address)
LEAD ATTORNEY

Counter Defendant**Bristol-Myers Squibb Sanofi
Pharmaceuticals Holding Partnership**

represented by **Robert L. Baechtold**
 (See above for address)
LEAD ATTORNEY

Thomas H. Beck
 (See above for address)
LEAD ATTORNEY

Date Filed	#	Docket Text
05/14/2002	1	COMPLAINT filed. Summons issued and Notice pursuant to 28 U.S.C. 636(c). FILING FEE \$ 150.00 RECEIPT # 439379. (gmo) (Entered: 05/23/2002)
05/14/2002	2	RULE 1.9 CERTIFICATE filed by Sanofi-Synthelabo . (gmo) (Entered: 05/23/2002)
05/14/2002	3	RULE 1.9 CERTIFICATE filed by Sanofi-Synthelabo . (gmo) (Entered: 05/23/2002)
05/14/2002	4	RULE 1.9 CERTIFICATE filed by Bristol-Myers Squibb . (gmo) (Entered: 05/23/2002)
05/14/2002	5	STATEMENT OF RELATEDNESS by Sanofi-Synthelabo, Sanofi-Synthelabo, Bristol-Myers Squibb re: that this action be filed as related to 1:02cv2255(RWS). (gmo) (Entered: 05/23/2002)
05/14/2002		CASE REFERRED TO Judge Robert W. Sweet as possibly related to 1:02cv2255. (gmo) (Entered: 05/23/2002)

05/14/2002		Mailed notice to Commissioner of Patents and Trademarks to report the filing of this action. (gmo) (Entered: 05/28/2002)
06/11/2002		Case accepted as related to 1:02cv2255. (gmo) (Entered: 06/11/2002)
06/11/2002	6	Notice of Case Assignment to Judge Robert W. Sweet . Copy of notice and judge's rules mailed to Attorney(s) of record: Thomas H. Beck, Robert L. Baechtold . (gmo) (Entered: 06/11/2002)
06/11/2002		Magistrate Judge Ronald L. Ellis is so designated. (gmo) (Entered: 06/11/2002)
06/13/2002		STIPULATION and ORDER; consolidating this action with action #02 cv 2255 for discovery and pretrial purposes. Consolidation for trial may be considered at a later time; the hearing scheduled for 6/12/02 is cancelled . (signed by Judge Robert W. Sweet) Original document filed under case number 02 cv 2255, document number 14. (jp) (Entered: 06/16/2002)
06/17/2002	7	RULE 1.9 CERTIFICATE filed by Dr. Reddy's Labs . (sb) (Entered: 06/20/2002)
06/17/2002	8	RULE 1.9 CERTIFICATE filed by Dr. Reddy's Lab . (sb) (Entered: 06/20/2002)
06/17/2002	9	ANSWER to Complaint; jury demand and COUNTERCLAIM by Dr. Reddy's Labs, Dr. Reddy's Lab (Attorney Andrew J. Miller) against Sanofi-Synthelabo, Sanofi-Synthelabo, Bristol-Myers Squibb ; Firm of: Budd Lerner, et al. by attorney Andrew J. Miller for defendant Dr. Reddy's Lab (sb) (Entered: 06/20/2002)
06/24/2002	12	RULE 1.9 CERTIFICATE filed by Sanofi-Synthelabo . (yv) (Entered: 07/02/2002)
06/25/2002	10	RULE 1.9 CERTIFICATE filed by Bristol-Myers Squibb . (yv) (Entered: 07/02/2002)
06/25/2002	11	RULE 1.9 CERTIFICATE filed by Sanofi-Synthelabo . (yv) (Entered: 07/02/2002)
07/08/2002	13	REPLY by Sanofi-Synthelabo, Sanofi-Synthelabo, Bristol-Myers Squibb to [9-2] counter claim; Firm of: Fitzpatrick, Cella, Harper & Scinto by attorney Robert L. Baechtold for counter-defendant Bristol-Myers Squibb, Thomas H. Beck for counter-defendant Bristol-Myers Squibb (db) (Entered: 07/15/2002)
07/22/2002	14	Letter filed by Dr. Reddy's Labs, Dr. Reddy's Lab addressed to Judge Sweet from Stuart D. Sender, dated June 5, 2002, re: consolidation of the two cases for pretrial purposes. (sv) (Entered: 07/25/2002)
12/16/2002		STIPULATION and ORDER, Completion of Fact Discovery 8/29/03 , Fact Depositions Begin 2/15/03 , Completion of Document Production to be completed by 2/1/03; Plaintiffs to Provide List of Asserted Claims to Defendants 6/9/03; Exchange Contention Interrogatories 6/16/03;

		Exchange Responses to Contention Interrogatories 7/16/03; Exchange Rebuttal Contention Interrogatories 7/23/03; Exchange Responses to Rebuttal Contention Interrogatories 8/22/03 . signed by Judge Robert W. Sweet) Original entry in 02cv2255 document number 35. (yv) (Entered: 12/18/2002)
01/31/2003		Memo-Endorsement on letter addressed to Judge Sweet from William E. Solander, dated 1/30/03. Reset plaintiffs' response to request for production of documents due for 2/28/03 ; Reset the start date of depositions to 3/3/03. Denying Dr. Reddy's unrelated requests . (signed by Judge Robert W. Sweet); (Orig. entry is docketed in 02 civ. 2255 as doc. #40). (kw) Modified on 02/07/2003 (Entered: 02/07/2003)
04/03/2003		STIPULATION and ORDER, regarding procedures that will govern the handling of confidential information (signed by Judge Robert W. Sweet); orig docketed in 02 cv 2255, doc #44 (cd) (Entered: 04/04/2003)
08/05/2003	15	STIPULATION and ORDER; Pursuant to Rule 41(a)(1)(ii) of the F.R.C.P., plaintiffs' Complaint for patent infringement with respect to United States Patent NO. 5,576,328 ("the '328 patent") shall be and hereby is, dismissed with prejudice ; Pursuant to Rule 41(c) of the F.R.C.P., Counts I, and II, with respect to the '328 patent, and Count III, in its entirety, of Dr. Reddy's Answer and Counterclaims shall be hereby are, dismissed without prejudice ; Sanofi will not assert the '328 patent against Dr. Reddy's or any other person on the basis of Dr. Reddy's present Abbreviated New Drug Application No. 76-273 ('ANDA no. 76-273"), including any minor amendments thereto, or on the basis of the sale, offer for sale, manufacture, import, export or use of the tablet product or clopidogrel bisulfate bulk drug substance which are the subject of ANDA No. 76-273. Sanofi agrees that any assignee, owner or licensee of any right to the '328 patent is bound by this Stipulation and Order . (signed by Judge Robert W. Sweet) (jco) (Entered: 08/07/2003)
08/11/2003	16	ANSWER by Dr. Reddy's Labs, Dr. Reddy's Lab to Amended Complaint. (Attorney Stuart D. Sender from the Firm: Budd Lerner, et. al.); jury demand. (moc) (Entered: 08/18/2003)
08/11/2003	16	COUNTERCLAIM by Dr. Reddy's Labs, Dr. Reddy's Lab against Sanofi-Synthelabo, Sanofi-Synthelabo, Bristol-Myers Squibb (moc) (Entered: 08/18/2003)
08/25/2003	17	REPLY by Sanofi-Synthelabo, Sanofi-Synthelabo, Bristol-Myers Squibb to [16-1] first amended counterclaim ; Firm of: Fitzpatrick, Cella, Harper & S by attorney Robert L. Baechtold for counter-defendant Bristol-Myers Squibb, Thomas H. Beck for counter-defendant Bristol-Myers Squibb (sb) (Entered: 08/28/2003)
08/26/2003		STIPULATION and ORDER, that the parties stipulate, subject to the consent of the Court, to the pre-trial schedule set forth herein: Completion of fact discovery is 10/15/03; All other deadlines are set accordingly . (signed by Judge Robert W. Sweet); Original document entered in Case #02cv2255(RWS), Doc. #53. (tp) (Entered: 08/27/2003)

10/10/2003		SEALED DOCUMENT placed in vault. [docketed as doc#56 in 02cv2255] (kre) (Entered: 10/14/2003)
11/04/2003		ORDER, defendants, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. produce 10 grams of their bulk clopidogrel bisulfate product and 10 of their clopidogrel bisulfate tablets to plaintiffs within 21 days from 10/29/03, namely on 11/19/03, to be delivered to the New York Offices of Fitzpatrick, Cella, Harper & Scinto , the schedule ordered by the Court on 8/21/03 shall be adhered to by all parties . (signed by Judge Robert W. Sweet); Original entry in 02cv2255 document number 69. (yv) (Entered: 11/06/2003)
11/14/2003		REDDY's OPENING CLAIM CONSTRUCTION BRIEF. Original document # 70 filed in 02cv2255. (sb) (Entered: 11/19/2003)
11/14/2003		Apotex Corp. and Apotex, Inc.'s Opening Claim Construction Brief. Original document # 71 filed in 02cv2255. (sb) (Entered: 11/19/2003)
11/26/2003	18	Letter addressed to Judge Sweet from Thomas H. Beck dated 11/25/03 re: response to Dr. Reddy's 11/24/03 letter to the Court. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc. (yv,) (Entered: 12/05/2003)
12/02/2003	20	Letter addressed to Judge Sweet from Thomas H. Beck dated 11/4/03 re: request for an order compelling defendant Dr. Reddy to update its production of its drug master file (DMF) for the accused product, clopidogrel bisulfate. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc..(db,) (Entered: 12/15/2003)
01/29/2004		PLAINTIFFS' RESPONSIVE BRIEF in support of Plaintiffs' proposed construction of claim 3. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc. Received in the night deposit box on 1/29/04 at 6:25 p.m. Original document # 77 filed in 02-cv-2255.(sb,) (Entered: 02/04/2004)
01/29/2004		RESPONSIVE CLAIM CONSTRUCTION BRIEF. Document filed by Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. Original document # 78 filed in 02-cv-2255. (sb,) (Entered: 02/09/2004)
02/11/2004		MOTION for Reconsideration of Court Opinion and Order dated 1/28/03.Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc. Original document filed in 02cv2255 (RWS), document # 81. (db,) (Entered: 02/17/2004)
02/25/2004	21	NOTICE OF CASE REASSIGNMENT to Judge Sidney H. Stein. Judge Robert W. Sweet no longer assigned to the case. (gf,) (Entered: 02/26/2004)
02/25/2004		Mailed notice to the attorney(s) of record. (gf,) (Entered: 02/26/2004)
05/12/2004		STIPULATION AND ORDER; that for the purposes of this litigation,

		subject to the consent of the Court, that claim 3 of U.S. Patent 4,847,265 has the construction that is set forth in this Stipulation and Order. (orig. document docketed in 02cv2255 as document #85). (Signed by Judge Sidney H. Stein on 5/7/04) (pl,) (Entered: 05/13/2004)
05/13/2004		ADDENDUM TO STIPULATED PROTECTIVE ORDER; that subject to the approval of the Court, Paragraph 3(a) is amended with respect to the attorneys for dft. Apotex, Inc. and Apotex Corp. to add the following Langer & Grogan, P.C., 1600 Market Street, Suite 2020, Philadelphia, PA 19103-7218. (Signed by Judge Sidney H. Stein on 5/12/04). (orig. document docketed in 02cv2255 as document #86).(pl,) (Entered: 05/14/2004)
08/13/2004		STIPULATION AND ORDER; that on consent of the Court, the pretrial schedule is as follows: Completion of document production by 2/1/05; Fact Depositions begin 2/15/03; completion of fact discovery by 10/15/03; Rebuttal to expert reports by 7/14/04; Reply to Expert Reports by 8/30/04; pretrial Order due 30 days after close of expert depositions 12/8/04; additional deadlines are as set forth in this Stipulation and Order. (Signed by Judge Sidney H. Stein on 8/10/04); (orig. document docketed in 02cv2255 as document #87) (Signed by Judge Sidney H. Stein on 8/10/04) (pl,) (Entered: 08/17/2004)
09/10/2004	22	MEMORANDUM OF LAW in Opposition to dft. motion for leave to amended answer, affirmative defenses and counterclaims. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc.. (pl,) (Entered: 09/17/2004)
09/27/2004		Order granting Apotex's motion for admission pro hac vice of Howard Israel Langer and John James Grogan as co counsel Apotex, Inc. and Apotex Corp.. (Signed by Judge Sidney H. Stein on 9/22/04) Original document filed in case #02cv2255, document #95.(dle,) (Entered: 09/28/2004)
09/27/2004		Transmission to Attorney Admissions Clerk. Transmitted re: Order Admitting Attorney Pro Hac Vice,, to the Attorney Admissions Clerk for updating of Attorney Information. (dle,) (Entered: 09/28/2004)
12/22/2004		AMENDED RULE 7.1 DISCLOSURE STATEMENT. Document filed by Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Sanofi-Synthelabo, Sanofi-Synthelobo, Inc..Original document filed in case #02cv2255, document #96.(dle,) (Entered: 12/27/2004)
12/22/2004		AMENDED RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Synthelobo, Inc. Original document filed in case #02cv2255, document #97.(dle,) (Entered: 12/27/2004)
12/22/2004		AMENDED RULE 7.1 DISCLOSURE STATEMENT. Document filed by Sanofi-Synthelabo.Original document filed in case #02cv2255, document #98.(dle,) (Entered: 12/27/2004)
01/11/2005		OPPOSITION TO PLAINTIFFS' MEMORANDUM OF LAW IN

		SUPPORT OF ITS MOTION FOR CONSOLIDATION filed by Apotex, Inc. and Apotex Corp.'s (orig. document docketed in 02cv2255 as document #102). (pl,) (Entered: 01/20/2005)
01/11/2005		DECLARATION of Karen J. Bernstein in Support re: Reply Memorandum of Law in Support of Motion. (orig. document docketed in 02cv2255 as document #103). (pl,) (Entered: 01/20/2005)
01/11/2005		REPLY in support of re: [88] MOTION (FILED ON SERVICE DATE) for Leave to File supplemental Third Amended Answer, Affirmative Defenses and Counterclaims. (orig. document docketed in 02cv2255 as document #104). (pl,) (Entered: 01/20/2005)
01/11/2005		DECLARATION of Karen J. Bernstein in Support of Apotex, Inc. and Apotex Corp.'s opposition to plaintiffs' Memorandum of Law in support of its motion for consolidation. (orig. document docketed in 02cv2255 as document #105). (pl,) (Entered: 01/20/2005)
02/23/2005		ORDER; that Apotex's application to depose Dr. Robert W Colman is denied. (orig. docketed in 02cv2255 as document #114). (Signed by Judge Sidney H. Stein on 2/18/05) (pl,) (Entered: 03/01/2005)
03/25/2005		STIPULATION AND ORDERThe Court amends the pretrial schedule as follows:All parties exchange their portions of the Pre-trial order, e.g., exhibit lists, deposition designations, witness lists etc by 4/22/2005; All parties exchange objections by 5/6/2005; Plaintiffs submit Pre-trial order to the COurt on 5/13/2005; Trial, pursuant to Court order. Original filed in 02cv2255. (Signed by Judge Sidney H. Stein on 3/16/2005) (jsa,) (Entered: 03/28/2005)
03/25/2005		Set/Reset Deadlines: Pretrial Order due by 5/13/2005. Proposed Pretrial Order due by 4/22/2005. (jsa,) (Entered: 03/28/2005)
03/25/2005		MEMORANDUM AND OPINION # 91403. The Court grants Sanofi's motion for reconsideration of Judge Sweet's decision, and upon reconsideration, denies Apotex's motion to compel Sanofi to produce deposition witnesses and all correspondence after 11/4/88 bearing on the issue of why Sanofi cancelled original claims 6-9 in its presecution of patent application 07/155,550. So Ordered. Original filed in case 02cv2255, doc #122. (Signed by Judge Sidney H. Stein on 3/23/05) (jco,) (Entered: 03/28/2005)
04/15/2005		ORDER that for the reasons set forth in this order, the court denies Apotex's motion for leave to supplement its third amended answer, affirmative defenses and counterclaims. (Signed by Judge Sidney H. Stein on 4/12/05) Original document filed in case #02cv2255, document #123.(dle,) (Entered: 04/19/2005)
04/25/2005	23	ENDORSED LETTER addressed to Judge Stein from Richard J. Stark dated 4/25/05 re: allowing an update to the court on the results of the negotiations on Friday, 5/6. (Signed by Judge Sidney H. Stein on s) (pl,) (Entered: 05/10/2005)

04/27/2005		MOTION (FILED ON SERVICE DATE) for Reconsideration of Order dated 4/12/05 denying defendants' motion for leave to amend to assert an additional ground of inequitable conduct. Document filed by Apotex Corp., Apotex, Inc. (Orig. doc. filed in case no. 02 cv 2255, as doc. #125) (ae,) (Entered: 05/03/2005)
05/20/2005		LETTER addressed to Judge Sidney H. Stein from Karen J. Bernstein dated 5/18/05 re: Opposition to Sanofi Plaintiffs' request to substitute Dr. Topol for Dr. Bhatt as its expert witness. Original document filed in case 02cv2255 as document #130. Document filed by Apotex Corp., Apotex, Inc..(ps,) (Entered: 05/25/2005)
05/24/2005		Addendum to STIPULATION PROTECTIVE ORDER: subject to the approval of the Court, Teva shall be a party to the Stipulated Protective Order. Teva shall have the same privileges and responsibilities concerning Confidential Information as all other parties to the Stipulated Protective Order. Attorneys of record for Teva, eligible for access to Confidential Information under Paragraph 3 of the Stipulated Protective Order, shall include: Kirland & Ellis LLP. (Original entry is docketed in 02 civ. 2255 as doc. #131). (Signed by Judge Sidney H. Stein on 5/20/05) (kw,) (Entered: 05/26/2005)
05/27/2005		ORDER. Plaintiffs Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership's request to substitute Dr. Deepak Bhatt for Dr. Eric J. Topol is granted pending the submission to this Court of Topol's affidavit setting forth the circumstances of and reasons for his withdrawal. Pending plaintiffs' submission of Dr. Eric J. Topol's affidavit setting forth the circumstances of and reasons for his withdrawal, the Court grants Sanofi's request to modify the scheduling Order dated 8/10/04. This modification is for the sole purpose of permitting plaintiffs to substitute the expert report of Dr. Deepak Bhatt. Plaintiffs shall serve and file Topol's affidavit on or before 6/6/05. Since plaintiffs delivered Bhatt's expert report to defendants on 4/15/05, defendants shall respond to Bhatt's report and depose Bhatt on or before 6/27/05 (Signed by Judge Sidney H. Stein on 5/26/05) Original entry in 02cv2255 document number 133.(yv,) (Entered: 05/31/2005)
06/07/2005		MOTION (FILED ON SERVICE DATE) for an Order admitting Kevin A. Keeling Pro Hac Vice as co-counsel. Document filed by Apotex Corp., Apotex, Inc. Original entry in 02cv2255 document number 135. (yv,) (Entered: 06/09/2005)
06/07/2005		DECLARATION of Kevin A. Keeling in Support re: MOTION (FILED ON SERVICE DATE) for Kevin A. Keeling to Appear Pro Hac Vice. Proposed Order attached. Document filed by Apotex Corp., Apotex, Inc. Original entry in 02cv2255 document number 136. (yv,) (Entered: 06/09/2005)
06/09/2005		ORDER; re: granting MOTION (FILED ON SERVICE DATE) for Kevin A. Keeling to Appear Pro Hac Vice. filed by Apotex, Inc., Apotex Corp., (orig. document docketed in 02cv2255 as document #137).

		(Signed by Judge Sidney H. Stein on 6/7/05) (pl,) (Entered: 06/13/2005)
07/01/2005		ORDER ADMITTING ATTORNEY PRO HAC VICE. William Charles Youngblood is permitted to appear pro hac vice in association with movant as co counsel to Apotex Inc. and Apotex Corp. in this action. (Signed by Judge Sidney H. Stein on 7/1/05) (dle,) Original document filed in case #02cv2255, document #139. (Entered: 07/06/2005)
07/15/2005		Proposed Voir Dire Questions. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv3672 (SHS), document # 176.(db,) (Entered: 09/09/2005)
07/15/2005		PRETRIAL MEMORANDUM OF LAW on Order of Proof at Trial in View of admission of infringement. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 177.(db,) (Entered: 09/09/2005)
07/15/2005		Proposed Jury Instructions. Document filed by Apotex Corp., Apotex, Inc.(db,) Modified on 9/9/2005 (db,). Original document filed in 02cv2255, document # 178. (Entered: 09/09/2005)
07/15/2005		PROPOSED VERDICT FORM. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 179. (db,) (Entered: 09/09/2005)
09/29/2005		REPLY MEMORANDUM OF LAW in Support of Apotex' motion to strike plaintiffs' motion to preclude relitigation of facts found by the federal court of Canada. Document filed by Apotex Corp., Apotex, Inc.. (dle,) Modified on 9/30/2005 (dle,). Original document filed in case #02cv2255, document #186. (Entered: 09/30/2005)
11/07/2005		MEMORANDUM OF LAW in Opposition to plaintiffs' motion in limine to preclude testimony of Michael Sofocleous. Document filed by Apotex Corp., Apotex, Inc.Original document filed in 02cv2255 (SHS), document # 191. Document filed by Apotex Corp., Apotex, Inc. (db,) (Entered: 11/08/2005)
11/07/2005		DECLARATION of Karen J. Bernstein in Support of memorandum in support of motion in limine to preclude testimony of Michael Sofocleous. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 192. (db,) (Entered: 11/08/2005)
11/07/2005		DECLARATION of Karen J. Bernstein in Support of memorandum in support of memorandum of law opposing plaintiff's motion to preclude relitigation of facts found by the federal court of Canada. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 193. (db,) (Entered: 11/08/2005)
11/07/2005		EXHIBIT (VOLUME I) to DECLARATION of Karen J. Bernstein in Support of memorandum in support of memorandum of law opposing plaintiff's motion to preclude relitigation of facts found by the federal court of Canada. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 194. (db,) (Entered: 11/08/2005)

		11/08/2005)
11/07/2005		EXHIBIT (VOLUME II) to DECLARATION of Karen J. Bernstein in Support of memorandum in support of memorandum of law opposing plaintiff's motion to preclude relitigation of facts found by the federal court of Canada. Document filed by Apotex Corp., Apotex, Inc. Original document filed in 02cv2255 (SHS), document # 195. (db,) (Entered: 11/08/2005)
12/22/2005		REPLY MEMORANDUM OF LAW in Support of Motrio to Preclude plaintiffs from Offering Evidence of Copying as a Secondary Consideration of Non-Obviousness (Apotex Motin NO. 15). Document filed by Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.. (orig. docmt dktd in case no. 02 cv 2255, docmt #230) (dj,) (Entered: 12/27/2005)
01/03/2006		ENDORSED LETTER: addressed to Judge Sidney H. Stein from Karen J. Bernstein dated 12/22/05 re: Requests a one week extension of the deadline for filing of reply briefs in support of its in limine motions from January 6, 2006 to January 13, 2006. ENDORSEMENT: So Ordered. (Original Doc. filed in case # 02cv2255 Document #239) (Signed by Judge Sidney H. Stein on 12/28/05) (js,) (Entered: 01/04/2006)
01/04/2006		REPLY MEMORANDUM OF LAW to plaintiffs' opposition to motion to exclude experts' opinions that examiner's rejection of claims was erroneous(Motion No. 20). Document filed by Apotex Corp., Apotex, Inc. Original filed in case 05cv2255, doc #241. (jco,) (Entered: 01/05/2006)
01/04/2006		REPLY MEMORANDUM OF LAW to plaintiffs' opposition to defendants' motion to exclude Sanofi's Opinions and Contentions that differences in the toxicity of the enantiomers in the acute toxicity study in the '265 Patent were "unexpected" (Apotex motion no. 17). Original filed in case 05cv2255 doc #242. Document filed by Apotex Corp., Apotex, Inc. (jco,) (Entered: 01/05/2006)
02/14/2006	24	NOTICE OF APPEARANCE by Karen Jill Bernstein on behalf of Apotex Corp., Apotex, Inc. (jco,) (Entered: 02/15/2006)
03/01/2006	25	ORDER: The trial date is hereby adjourned from 4/3 to 6/12/2006 at 9:30 a.m. (Signed by Judge Sidney H. Stein on 2/27/2006) (lb,) (Entered: 03/01/2006)
03/14/2006		ADDENDUM TO STIPULATED PROTECTIVE ORDER...regarding procedures to be followed that shall govern the handling of confidential material....(original filed in 02-cv-2255 as document # 263) (Signed by Judge Sidney H. Stein on 3/13/2006) (lb,) (Entered: 03/14/2006)
10/23/2006		REPLY MEMORANDUM OF LAW in Support to Apotex's Motion for Leave to File a Supplemental Pleading. (orig. document docketed in 02cv3672 as document #332). Document filed by Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc. (pl,) (Entered: 10/24/2006)

PACER Service Center			
Transaction Receipt			
11/09/2007 08:53:24			
PACER Login:	dp0001	Client Code:	22183-1029
Description:	Docket Report	Search Criteria:	1:02-cv-03672-SHS
Billable Pages:	8	Cost:	0.64
